WO2003033483A1 - Biphenylcarboxylic amide derivatives as p38 kinase inhibitors - Google Patents

Biphenylcarboxylic amide derivatives as p38 kinase inhibitors Download PDF

Info

Publication number
WO2003033483A1
WO2003033483A1 PCT/EP2002/011572 EP0211572W WO03033483A1 WO 2003033483 A1 WO2003033483 A1 WO 2003033483A1 EP 0211572 W EP0211572 W EP 0211572W WO 03033483 A1 WO03033483 A1 WO 03033483A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
methyl
halogen
compound
Prior art date
Application number
PCT/EP2002/011572
Other languages
French (fr)
Inventor
Richard Martyn Angell
Nicola Mary Aston
Paul Bamborough
Mark James Bamford
George Stuart Cockerill
Stephen Sean Flack
Dramane Ibrahim Laine
Ann Louise Walker
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to EP02782928A priority Critical patent/EP1436272B1/en
Priority to US10/492,697 priority patent/US7151118B2/en
Priority to JP2003536223A priority patent/JP2005508967A/en
Priority to DE60226469T priority patent/DE60226469D1/en
Publication of WO2003033483A1 publication Critical patent/WO2003033483A1/en
Priority to US11/556,285 priority patent/US7309800B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to novel compounds and their use as pharmaceuticals, particularly as p38 kinase inhibitors, for the treatment of certain diseases and conditions.
  • X is a bond or a phenyl group which may be optionally substituted
  • R 1 is selected from an optionally substituted five- to seven-membered heterocyclic ring, an optionally substituted five- to seven-membered heteroaryl ring and an optionally substituted fused bicyclic ring;
  • R 2 is selected from hydrogen, C ⁇ alkyl and -(CH 2 ) p -C 3 . 7 cycloalkyl; or when X is a bond and m and n are both zero, R 1 and R 2 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen and nitrogen, which can be optionally substituted by C h alky!
  • R 3 is the group -NH-CO-R 4 ;
  • R 4 is selected from hydrogen, C ⁇ alkyl, C ⁇ . 6 alkoxy, -(CH 2 ) q -C 3 . 7 cycloalkyl, trifluoromethyl, -(CH 2 ) r phenyl optionally substituted by R 5 and/or R 6 , -(CH 2 ) r heteroaryl optionally substituted by R 5 and/or R 6 , -(CH 2 ) r heterocyclyl optionally substituted by R 5 and/or R 6 and -(CH 2 ) r fused bicyclyl optionally substituted by R 5 and/or R 6 ;
  • R 5 is selected from d. 6 alkyl, d-ealkoxy, -(CH 2 ) q -C 3 - 7 cycloalkyl, -CONR 7 R 8 , - NHCOR 8 , -S0 2 NHR 7 , -NHS0 2 R 8 , halogen, -(CH 2 ) S NR 9 R 10 , oxy, trifluoromethyl, phenyl optionally substituted by one or more R 6 groups and heteroaryl wherein the heteroaryl may be optionally substituted by one or more R 6 groups;
  • R 6 is selected from d. 6 alkyl, d. 6 alkoxy, halogen, trifluoromethyl and -NR 9 R 10 ; or R 5 and R 6 , together with the carbon atoms to which they are bound, form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R 5 and R 6 may optionally contain one or two heteroatoms selected from oxygen, nitrogen and sulfur;
  • R 7 is selected from hydrogen, d. 6 alkyl and phenyl wherein the phenyl group may be optionally substituted by one or more R 6 groups;
  • R 8 is selected from hydrogen and d_ 6 alkyl; or R 7 and R 8 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R x , wherein the ring may be substituted by up to two d- ⁇ alkyl groups;
  • R is selected from hydrogen and methyl;
  • R 9 is selected from hydrogen, d. 6 alkyl and -(CH 2 ) q -C 3 . 7 cycloalkyl optionally substituted by d_ 6 alkyl;
  • R 10 is selected from hydrogen and d. 6 alkyl; or R 9 and R 10 , together with the nitrogen atom to which they are bound, form a three- to seven-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and nitrogen, wherein the ring may contain up to one double bond and the ring may be substituted by one or more R 11 groups;
  • R 11 is selected from d. 6 alkyl, oxy, -CH 2 OC 1 - 6 alkyl, trichloromethyl and -N(d- 6 alkyl) 2 ;
  • U is selected from methyl and halogen;
  • W is selected from methyl and chlorine
  • V and Y are each selected independently from hydrogen, methyl and halogen; m and n are independently selected from 0, 1 and 2, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups selected independently from d. 6 alkyl and the sum of m+ n is from 0 to 4; p, q and r are independently 0 or 1; s is O, 1, 2 or 3; t is selected from 0, 1 and 2; or a pharmaceutically acceptable salt or solvate thereof.
  • a compound of formula (IA) wherein R 1 , R 2 , R 3 , m, n and X are as defined above, or a pharmaceutically acceptable salt or solvate thereof.
  • the molecular weight of a compound of formula (I) does not exceed 1000, more preferably 800, even more preferably 600.
  • the group R 1 may be optionally substituted by up to three substituents, more preferably one or two substituents, selected from d. 6 alkyl, d ⁇ alkoxy, oxy, halogen, hydroxyd-ealkyl, -N(C ⁇ -6alkyl) 2 , -CH 2 -N(C 1 - 6 alkyl) 2 , -CO 2 C 1 ⁇ alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano.
  • substituents for X are selected independently from d- 6 alkyl, d ⁇ alkoxy, halogen, trifluoromethyl, trifluoromethoxy, and cyano. Particularly preferred substituents are methyl, chloro, fluoro, cyano, methoxy and trifluoromethoxy. X may also be optionally substituted by C 3 . 7 cycloalkyl.
  • R 1 is preferably an optionally substituted group selected from pyrrolidinyl, furyl, pyrrolyl, imidazolyl, imidazolidinyl, pyrazolyl, tetrazolyl, oxazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholino, pyridyl, pyrimidinyl, thienyl, benzimidazolyl and quinolyl.
  • Particularly preferred optional substituents are methyl and oxy.
  • R 1 is selected from an optionally substituted pyrrolidinyl, isoxazolyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholino, pyridyl, tetrahydrofuranyl, tetrahydrothiophenyl and quinolyl.
  • Particularly preferred groups are piperazinyl, piperidinyl, morpholino, imidazolyl, thienyl and pyrrolidinyl.
  • R 1 when X is a bond are selected independently from d- ⁇ alkyl, d- 6 alkoxy, oxy, halogen, hydroxyC ⁇ alkyl, -N(C ⁇ - 6 alkyl) 2 , -CH 2 -N(d- 6 alkyl) 2 , -C0 2 C 1 ⁇ alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano. Particularly preferred optional substituents are methyl and oxy.
  • R 2 is selected from hydrogen, C 1 - alkyl and -CH 2 - cyclopropyl, more preferably hydrogen.
  • R 4 is selected from -(CH 2 ) r phenyl optionally substituted by R 5 and/or R 6 and -(CH 2 ) r heteroaryl optionally substituted by R 5 and/or R 6 .
  • R 4 is -(CH 2 ) r heteroaryl optionally substituted by
  • R 5 and/or R 6 especially furyl, thienyl, isoxazolyl or pyridyl optionally substituted by - (CH 2 ) S NR 9 R 10 .
  • R 5 is selected from d ⁇ alkyl, halogen, - NR 9 R 10 , C 3 . 6 cycloalkyl, phenyl optionally substituted by one or more R 6 groups and heteroaryl optionally substituted by one or more R 6 groups.
  • R 6 is selected from C 1 . 2 alkyl and halogen.
  • R 6 is -NR 9 R 10 .
  • R 7 is selected from hydrogen and d ⁇ alkyl.
  • R 8 is selected from hydrogen and C 1 - 4 alkyl.
  • R 9 is selected from hydrogen, C ⁇ --.alkyl, C 3 - 6 cycloalkyl and -CH 2 C 3 - 6 cycloalkyl.
  • R 9 and R 10 together with the nitrogen atom to which they are bound, form a five to six membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R x , wherein R is methyl, and the ring may be substituted by one or more R 11 groups.
  • R 9 and R 10 together with the nitrogen atom to which they are bound, form a pyrrolidinyl group.
  • R 11 is selected from methyl and oxy.
  • W is methyl.
  • V and Y are each selected independently from hydrogen, chlorine and fluorine. In a further preferred embodiment, V is fluorine.
  • n and n are independently selected from 0, 1 and 2, and the sum of m+n is from 0-3.
  • q is 0.
  • r is 0.
  • s is selected from 0, 1 and 2.
  • t is selected from 0 and 1. In particular, t is 0.
  • alkyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms.
  • d. 6 alkyl means a straight or branched alkyl containing at least 1 , and at most 6, carbon atoms.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl and t-butyl.
  • a d ⁇ alkyl group is preferred, for example methyl, ethyl or isopropyl.
  • the said alkyl groups may be optionally substituted with one or more halogen atoms, in particular fluorine atoms, for example, trifluoromethyl.
  • alkoxy refers to a straight or branched chain alkoxy group, for example, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2- methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy, or hexyloxy.
  • a d ⁇ alkoxy group is preferred, for example methoxy or ethoxy.
  • cycloalkyl refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms.
  • C 3 - 7 cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms.
  • cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • a C 3 . 5 cycloalkyl group is preferred, for example cyclopropyl.
  • heteroaryl ring and “heteroaryl” refer to a monocyclic five- to seven-membered unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur.
  • the heteroaryl ring has five or six ring atoms.
  • heteroaryl rings include, but are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl,
  • the said ring may be optionally substituted by one or more substituents independently selected from d ⁇ alkyl and oxy.
  • heterocyclic ring and heterocyclyl refer to a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur.
  • the heterocyclyl ring has five or six ring atoms.
  • heterocyclyl groups include, but are not limited to, aziridinyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholino, tetrahydropyranyl, tetrahydrofuryl, and thiomorphilino.
  • the said ring may be optionally substituted by one or more substituents independently selected from d. 6 alkyl and oxy.
  • fused bicyclic ring system and “fused bicyclyl” refer to a ring system comprising two five- to seven-membered saturated or unsaturated rings, the ring system containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, each ring has five or six ring atoms.
  • suitable fused bicyclic rings include, but are not limited to, naphthyl, indolyl, indolinyl, benzothienyl quinolyl, isoquinolyl, tetrahydroquinolyl, benzodioxanyl, indanyl and tetrahydronaphthyl.
  • Each ring may be optionally substituted with one or more substituents independently selected from halogen, d ⁇ alkyl, oxy, -(CH 2 ) P NR 10 R 11 , - CO(CH 2 ) p NR 10 R 11 , and imidazolyl.
  • substituents are chlorine, imidazolyl and -CH 2 -N(CH 3 ) 2 .
  • halogen refers to the elements fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine. A particularly preferred halogen is fluorine.
  • the term "optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.
  • substituted refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent.
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • suitable solvents include water, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water.
  • Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism).
  • Salts of the compounds of the present invention are also encompassed within the scope of the invention and may, for example, comprise acid addition salts resulting from reaction of an acid with a nitrogen atom present in a compound of formula (I).
  • Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention.
  • Representative salts include the following salts: Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Calcium Edetate, Camsylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate,
  • Gluconate Glutamate, Glycollylarsanilate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isethionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Monopotassium Maleate, Mucate, Napsylate, Nitrate, N- methylglucamine, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate,
  • the compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.
  • a general method (A) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 1 below.
  • a general method (B) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 2 below.
  • a general method (E) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 5 below.
  • the acid compound (XIII) wherein R 4 is as defined above, under amide forming conditions (if desired, the acid compound (XIII) may be converted to an activated form of the acid, for example the acid chloride, and then the activated acid thus formed reacted with the amine compound (XII)); or
  • R1 , R2, X, m and n are as defined above, under amide forming conditions.
  • Suitable amide forming conditions are well known in the art and include treating a solution of the acid, in for example THF, with an amine in the presence of, for example, HATU and DIPEA.
  • the compounds, salts or solvates of the present invention are conveniently administered in the form of pharmaceutical compositions.
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the compounds of formula (I) and their pharmaceutically acceptable salts and solvates may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration.
  • the pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable salts and solvates.
  • a particularly preferred method of administration, and corresponding formulation, is oral administration.
  • the pharmaceutical composition may take the form of, and be administered as, for example, tablets (including sub-lingual tablets) and capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, emulsions, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.
  • Capsules can be made by preparing a powder mixture as described above, and filling formed gelatin sheaths.
  • Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation.
  • a disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
  • suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
  • a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate.
  • a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone
  • a solution retardant such as paraffin
  • a resorption accelerator such as a quaternary salt
  • an absorption agent such as bentonite, kaolin or dicalcium phosphate.
  • the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
  • the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
  • the lubricated mixture is then compressed into tablets.
  • the compounds of the present invention can also be combined with free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
  • a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or
  • Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
  • Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
  • Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
  • Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or saccharin, and the like can also be added.
  • dosage unit formulations for oral administration can be microencapsulated.
  • the formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • the compounds of the present invention can also be administered in the form of liposome emulsion delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • the present invention includes pharmaceutical compositions containing 0.1 to 99.5%, more particularly, 0.5 to 90% of a compound of the formula (I) in combination with a pharmaceutically acceptable carrier.
  • composition may also be administered in nasal, ophthalmic, otic, rectal, topical, intravenous (both bolus and infusion), intraperitoneal, intraarticular, subcutaneous or intramuscular, inhalation or insufflation form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • transdermal administration the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.
  • the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravasculariy or subcutaneously).
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • parenteral administration these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle.
  • the compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
  • Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions.
  • Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
  • the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropan
  • gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • the pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition.
  • the compositions are administered in an amount of active agent of at least about 100 ⁇ g/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, dose is from about 100 ⁇ g/kg to about 5 mg/kg body weight, daily.
  • the daily dosage level of the active agent will be from 0. 1 mg/kg to 10 mg/kg and typically around 1 mg/kg. It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The effectiveness of a selected actual dose can readily be determined, for example, by measuring clinical symptoms or standard anti-inflammatory indicia after administration of the selected dose.
  • the present invention provides a compound of formula (I) or a salt or solvate thereof, for use in therapy.
  • the compounds of the present invention are generally inhibitors of the serine/threonine kinase p38 and are therefore also inhibitors of cytokine production which is mediated by p38 kinase.
  • inhibitors of the serine/threonine kinase p38 are included those compounds that interfere with the ability of p38 to transfer a phosphate group from ATP to a protein substrate according to the assay described below.
  • the compounds of the invention may be selective for one or more of the isoforms of p38, for example p38 ⁇ , p38 ⁇ , p38 ⁇ and/or p38 ⁇ .
  • the compounds of the invention selectively inhibit the p38 ⁇ isoform.
  • the compounds of the invention selectively inhibit the p38 ⁇ isoform.
  • the compounds of the invention selectively inhibit the p38 ⁇ and p38 ⁇ isoforms.
  • Assays for determining the selectivity of compounds for the p38 isoforms are described in, for example, WO 99/61426, WO 00/71535 and WO
  • p38 kinase activity can be elevated (locally or throughout the body), p38 kinase can be incorrectly temporally active or expressed, p38 kinase can be expressed or active in an inappropriate location, p38 kinase can be constitutively expressed, or p38 kinase expression can be erratic; similarly, cytokine production mediated by p38 kinase activity can be occurring at inappropriate times, inappropriate locations, or it can occur at detrimentally high levels.
  • the present invention provides a method for the treatment of a condition or disease state mediated by p38 kinase activity, or mediated by cytokines produced by the activity of p38 kinase, in a subject which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.
  • the present invention also provides a method of inhibiting cytokine production which is mediated by p38 kinase activity in a subject, e.g. a human, which comprises administering to said subject in need of cytokine production inhibition a therapeutic, or cytokine-inhibiting, amount of a compound of the present invention.
  • the compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.
  • the present invention treats these conditions by providing a therapeutically effective amount of a compound of this invention.
  • therapeutically effective amount is meant a symptom-alleviating or symptom-reducing amount, a cytokine-reducing amount, a cytokine-inhibiting amount, a kinase-regulating amount and/or a kinase- inhibiting amount of a compound.
  • Such amounts can be readily determined by standard methods, such as by measuring cytokine levels or observing alleviation of clinical symptoms. For example, the clinician can monitor accepted measurement scores for anti-inflammatory treatments.
  • the compounds of the present invention can be administered to any subject in need of inhibition or regulation of p38 kinase or in need of inhibition or regulation of p38 mediated cytokine production.
  • the compounds may be administered to mammals.
  • mammals can include, for example, horses, cows, sheep, pigs, mice, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably, humans.
  • the present invention provides methods of treating or reducing symptoms in a human or animal subject suffering from, for example, rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs.
  • rheumatoid arthritis arthritis
  • osteoarthritis asthma
  • psoriasis eczema
  • a further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • a further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • a further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, neurodegenerative disease,
  • Alzheimer's disease, Parkinson's disease and epilepsy which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • a further aspect of the invention provides a method of treatment of a human or animal subject suffering from any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by p38 kinase activity.
  • a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs.
  • a condition or disease state selected from rheum
  • a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy, and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
  • a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy, and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
  • a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis,
  • Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
  • a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease and epilepsy.
  • a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain.
  • the compounds of formula (I) and their salts, solvates and physiologically functional salts and solvates may be employed alone or in combination with other therapeutic agents for the treatment of the above-mentioned conditions.
  • Examples of other pharmaceutically active agents which may be employed in combination with compounds of formula (I) and their salts and solvates for rheumatoid arthritis therapy include: immunosuppresants such as amtolmetin guacil, mizoribine and rimexolone; anti-TNF ⁇ agents such as etanercept, infliximab, diacerein; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subreum; interleukin 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as NRD-101 (Aventis); interleukin 1 receptor antagonists such as anakinra; CD8 antagonists such as amiprilose hydrochloride; beta amyloid precursor protein antagonists such as reumacon; matrix metalloprotease inhibitors such as cipemastat and other disease modifying anti-rheumatic drugs (DMARDs)
  • LCMS was conducted on a column (3.3cm x 4.6mm ID, 3um ABZ+PLUS), at a Flow Rate of 3ml/min, Injection Volume of 5 ⁇ l, at room temperature and UV Detection Range at 215 to 330nm.
  • Example 3 N-
  • Example 5 N-(4'-(f3-(4-Methylpiperazin-1 -yl)propylamino1carbonyl)-6-methyl-1 , 1 '- biphenyl-3-yl)-3-furamide a) 5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (50mg, 0.156mmol),
  • Example 6 N-(6-Methyl-4'-
  • Example 7 N-r4'-((r(1-t-Butyloxycarbonylpiperidin-4-yl)methvnamino>carbonyl)-6- methyl-1 , 1 '-biphenyl-3-v ⁇ -3-furamide 5'-(3-Furoylamino)-2'-methyl-1 , 1 '-biphenyl-4- carboxylic acid (50mg, 0.156mmol), 1-t-butyloxycarbonyl-4-aminomethylpiperidine (33.3mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21mg, 0.156mmol) and DIPEA (27 ⁇ l, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried
  • Methyl (3'-amino-6'-methyl-1,1'-biphen-4-yl)carboxylate (1.45g, 6.0mmol), thiophene-3- carboxylic acid (0.846g, 6.6mmol), HOBT (0.973g, 7.2mmol) and 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.38g, 7.2mmol) were dissolved in DMF (10ml). DIPEA (1.26ml, 7.2mmol) was added to the stirred solution, which was then stirred for 16 hours at 20°C. The solvent was removed in vacuo and the residue dissolved in ethyl acetate.
  • Methyl (3'-amino-6'-methyl-1,1'-biphen-4-yl)carboxylate (0.483g, 2.0mmol), isoxazole-3- carboxylic acid (0.248g, 2.2mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.460g, 2.4mmol) and HOBT (0.324g, 2.4mmol) were dissolved in DMF (5ml). DIPEA (420 ⁇ l, 2.4 mmol) was added to the solution, which was then stirred for 5 hours at 20°C. Ethyl acetate (50ml) and water (50ml) were added.
  • Example 17 N-r6-Methyl-4'-((f3-(morpholin-4-ylmethyl)benzvnamino)carbonyl)-1.1 '- biphenyl-3-v ⁇ -3-furamide
  • Example 18 tert-Butyl 4-f((f5'-(3-furoylamino)-2'-methyl-1.1 '-biphenyl-4- v ⁇ carbonyl>amino)methvnpiperidine-1-carboxylate
  • DMSO Dimethylsulphoxide HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HBTU O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate HOBT 1-Hydroxybenzotriazole hydrate
  • the peptide substrate used in the p38 assay was biotin-IPTSP.TTTYFFFRRR- amide.
  • the p38 and MEK6 proteins were purified to homogeneity from E.coli expression systems.
  • the fusion proteins were tagged at the N-terminus with Glutathione-S-Transferase (GST).
  • the maximum activation was achieved by incubating 20uL of a reaction mixture of 30nM MEK6 protein and 120nM p38 protein in the presence of 1.5uM peptide and 10mM Mg(CH 3 CO 2 ) 2 in 100mM HEPES, pH 7.5, added to 15uL of a mixture of 1.5uM ATP with O.O ⁇ uCi [g- 33 P]ATP, with or without 15uL of inhibitor in 6%DMSO.
  • the controls were reactions in the presence (negative controls) or absence (positive controls) of 50 mM EDTA.
  • ⁇ P38 Fluorescence Polarisation Method ⁇ P38 was prepared in house. SB4777790-R Ligand was diluted in HEPES containing MgCI 2 , CHAPS, DTT and DMSO. This was added to blank wells of a Black NUNC 384 well plate, ⁇ P38 was added to this ligand mixture then added to the remainder of the 384 well plate containing controls and compounds. The plates were read on an LJL Analyst and Fluorescence Anisotropy used to calculate the compound inhibition.

Abstract

Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

Description

BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS
This invention relates to novel compounds and their use as pharmaceuticals, particularly as p38 kinase inhibitors, for the treatment of certain diseases and conditions.
We have now found a group of novel compounds that are inhibitors of p38 kinase.
According to the invention there is provided a compound of formula (I):
Figure imgf000002_0001
wherein
X is a bond or a phenyl group which may be optionally substituted;
R1 is selected from an optionally substituted five- to seven-membered heterocyclic ring, an optionally substituted five- to seven-membered heteroaryl ring and an optionally substituted fused bicyclic ring;
R2 is selected from hydrogen, C^alkyl and -(CH2)p-C3.7cycloalkyl; or when X is a bond and m and n are both zero, R1 and R2, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen and nitrogen, which can be optionally substituted by Chalky!
R3 is the group -NH-CO-R4;
R4 is selected from hydrogen, C^alkyl, Cι.6alkoxy, -(CH2)q-C3.7cycloalkyl, trifluoromethyl, -(CH2)rphenyl optionally substituted by R5 and/or R6, -(CH2)rheteroaryl optionally substituted by R5 and/or R6, -(CH2)rheterocyclyl optionally substituted by R5 and/or R6 and -(CH2)rfused bicyclyl optionally substituted by R5 and/or R6;
R5 is selected from d.6alkyl, d-ealkoxy, -(CH2)q-C3-7cycloalkyl, -CONR7R8, - NHCOR8, -S02NHR7, -NHS02R8, halogen, -(CH2)SNR9R10, oxy, trifluoromethyl, phenyl optionally substituted by one or more R6 groups and heteroaryl wherein the heteroaryl may be optionally substituted by one or more R6 groups;
R6 is selected from d.6alkyl, d.6alkoxy, halogen, trifluoromethyl and -NR9R10; or R5 and R6, together with the carbon atoms to which they are bound, form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R5 and R6 may optionally contain one or two heteroatoms selected from oxygen, nitrogen and sulfur;
R7 is selected from hydrogen, d.6alkyl and phenyl wherein the phenyl group may be optionally substituted by one or more R6 groups; R8 is selected from hydrogen and d_6alkyl; or R7 and R8, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-Rx, wherein the ring may be substituted by up to two d-βalkyl groups; R is selected from hydrogen and methyl;
R9 is selected from hydrogen, d.6alkyl and -(CH2)q-C3.7cycloalkyl optionally substituted by d_6alkyl;
R10 is selected from hydrogen and d.6alkyl; or R9 and R10, together with the nitrogen atom to which they are bound, form a three- to seven-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and nitrogen, wherein the ring may contain up to one double bond and the ring may be substituted by one or more R11 groups;
R11 is selected from d.6alkyl, oxy, -CH2OC1-6alkyl, trichloromethyl and -N(d- 6alkyl)2; U is selected from methyl and halogen;
W is selected from methyl and chlorine;
V and Y are each selected independently from hydrogen, methyl and halogen; m and n are independently selected from 0, 1 and 2, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups selected independently from d.6alkyl and the sum of m+ n is from 0 to 4; p, q and r are independently 0 or 1; s is O, 1, 2 or 3; t is selected from 0, 1 and 2; or a pharmaceutically acceptable salt or solvate thereof. According to a further embodiment of the invention there is provided a compound of formula (IA):
Figure imgf000004_0001
wherein R1, R2, R3, m, n and X are as defined above, or a pharmaceutically acceptable salt or solvate thereof.
In a preferred embodiment, the molecular weight of a compound of formula (I) does not exceed 1000, more preferably 800, even more preferably 600.
The group R1 may be optionally substituted by up to three substituents, more preferably one or two substituents, selected from d.6alkyl, d^alkoxy, oxy, halogen, hydroxyd-ealkyl, -N(Cι-6alkyl)2, -CH2-N(C1-6alkyl)2, -CO2C1^alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano. When X is phenyl, the optional substituents for X are selected independently from d-6alkyl, d^alkoxy, halogen, trifluoromethyl, trifluoromethoxy, and cyano. Particularly preferred substituents are methyl, chloro, fluoro, cyano, methoxy and trifluoromethoxy. X may also be optionally substituted by C3.7cycloalkyl.
In a preferred embodiment, when X is phenyl, R1 is preferably an optionally substituted group selected from pyrrolidinyl, furyl, pyrrolyl, imidazolyl, imidazolidinyl, pyrazolyl, tetrazolyl, oxazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholino, pyridyl, pyrimidinyl, thienyl, benzimidazolyl and quinolyl. Particularly preferred groups are morpholino, pyrrolidinyl, imidazolyl, pyridyl, oxazolyl, oxadiazolyl, pyrazolyl, piperidinyl, piperazinyl and pyrimidinyl. The optional substituents for R1 when X is phenyl are selected independently from C^alkyl, d.6alkoxy, oxy, halogen, hydroxyCι--.alkyl, -
N(C1.6alkyl)2 and -CH2-N(C1.6alkyl)2. Particularly preferred optional substituents are methyl and oxy.
In a preferred embodiment, when X is a bond, R1 is selected from an optionally substituted pyrrolidinyl, isoxazolyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholino, pyridyl, tetrahydrofuranyl, tetrahydrothiophenyl and quinolyl. Particularly preferred groups are piperazinyl, piperidinyl, morpholino, imidazolyl, thienyl and pyrrolidinyl. The optional substituents for R1 when X is a bond are selected independently from d-βalkyl, d- 6alkoxy, oxy, halogen, hydroxyC^alkyl, -N(Cι-6alkyl)2, -CH2-N(d-6alkyl)2, -C02C1^alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano. Particularly preferred optional substituents are methyl and oxy. In a preferred embodiment, R2 is selected from hydrogen, C1- alkyl and -CH2- cyclopropyl, more preferably hydrogen.
In a preferred embodiment, R4 is selected from -(CH2)rphenyl optionally substituted by R5 and/or R6 and -(CH2)rheteroaryl optionally substituted by R5 and/or R6. In a particularly preferred embodiment, R4 is -(CH2)rheteroaryl optionally substituted by
R5 and/or R6, especially furyl, thienyl, isoxazolyl or pyridyl optionally substituted by - (CH2)SNR9R10. In a preferred embodiment, R5 is selected from d^alkyl, halogen, - NR9R10, C3.6cycloalkyl, phenyl optionally substituted by one or more R6 groups and heteroaryl optionally substituted by one or more R6 groups. In a preferred embodiment, R6 is selected from C1.2alkyl and halogen. In a further preferred embodiment, R6 is -NR9R10. In a preferred embodiment, R7 is selected from hydrogen and d^alkyl.
In a preferred embodiment, R8 is selected from hydrogen and C1-4alkyl.
In a preferred embodiment, R9 is selected from hydrogen, Cι--.alkyl, C3-6cycloalkyl and -CH2C3-6cycloalkyl.
In a preferred embodiment, R10 is selected from hydrogen and d^alkyl.
In a preferred embodiment, R9 and R10, together with the nitrogen atom to which they are bound, form a five to six membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-Rx, wherein R is methyl, and the ring may be substituted by one or more R11 groups. In a further preferred embodiment, R9 and R10, together with the nitrogen atom to which they are bound, form a pyrrolidinyl group.
In a preferred embodiment, R11 is selected from methyl and oxy.
In a preferred embodiment, W is methyl. In a preferred embodiment, V and Y are each selected independently from hydrogen, chlorine and fluorine. In a further preferred embodiment, V is fluorine.
In a preferred embodiment, m and n are independently selected from 0, 1 and 2, and the sum of m+n is from 0-3.
In a preferred embodiment, q is 0. In a preferred embodiment, r is 0.
In a preferred embodiment, s is selected from 0, 1 and 2.
In a preferred embodiment, t is selected from 0 and 1. In particular, t is 0.
It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove. Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable salts and solvates. Specific examples which may be mentioned include:
N-(6-Methyl-4'-{[3-(4-methylpiperazin-1-yl)propylamino]carbonyl}-1,1'-biphenyl-3- yl)-2-pyrrolidin-1-ylisonicotinamide; N-{6-Methyl-4'-[(3-morpholin-1-ylpropylamino)carbonyl]-1,1'-biphenyl-3-yl}-2- pyrrolidin-1 -ylisonicotinamide;
N-{4'-[(3-lmidazol-1-ylpropylamino)carbonyl]-6-methyl-1,1'-biphenyl-3-yl}-2- pyrrolidin-1 -ylisonicotinamide; N-{6-Methyl-4'-[(4-methylpiperazin-1 -yl)carbonyl]-1 , 1 '-biphenyl-3-yl}-2-pyrrolidin-
1 -ylisonicotinamide;
N-(6-Methyl-4'-{[(3-morphlin-4-ylmethylbenzyl)amino]carbonyl}-1 , 1 '-biphenyl-3- yl)-3-furamide;
N-[4'-({[(1-t-Butyloxycarbonylpiperidin-4-yl)methyl]amino}carbonyl)-6-methyl-1,1'- biphenyl-3-yl]-3-furamide; and
N-(6-Methyl-4'-{[2-(4-methylpiperazin-1-ylmethyl)anilino]carbonyl}-1,1'-biphenyl- 3-yl)-3-furamide.
Further specific examples which may be mentioned include:
N-[6-Methyl-4'-({[4-(4-methylpiperazin-1 -yl)benzyl]amino}carbonyl)-1 , 1 '-biphenyl- 3-yl]thiophene-3-carboxamide;
N-{6-Methyl-4'-[({3-[(4-methylpiperazin-1 -yl)methyl]phenyl}amino)carbonyl]-1 , 1 '- biphenyl-3-yl}thiophene-3-carboxamide;
N-[6-Methyl-4'-({[3-(morpholin-4-ylmethyl)benzyl]amino}carbonyl)-1 , 1 '-biphenyl-3- yl]-3-furamide; and N-[6-Methyl-4'-({[4-(4-methylpiperazin-1 -yl)benzyl]amino}carbonyl)-1 , 1 '-biphenyl-
3-yl]isoxazole-3-carboxamide.
As used herein, the term "alkyl" refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms. For example, d.6alkyl means a straight or branched alkyl containing at least 1 , and at most 6, carbon atoms. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl and t-butyl. A d^alkyl group is preferred, for example methyl, ethyl or isopropyl. The said alkyl groups may be optionally substituted with one or more halogen atoms, in particular fluorine atoms, for example, trifluoromethyl.
As used herein, the term "alkoxy" refers to a straight or branched chain alkoxy group, for example, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2- methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy, or hexyloxy. A d^alkoxy group is preferred, for example methoxy or ethoxy.
As used herein, the term "cycloalkyl" refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms. For example, C3-7cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms.
Examples of "cycloalkyl" as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A C3.5 cycloalkyl group is preferred, for example cyclopropyl. As used herein, the terms "heteroaryl ring" and "heteroaryl" refer to a monocyclic five- to seven-membered unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, the heteroaryl ring has five or six ring atoms. Examples of heteroaryl rings include, but are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, The said ring may be optionally substituted by one or more substituents independently selected from d^alkyl and oxy.
As used herein, the terms "heterocyclic ring" and heterocyclyl" refer to a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, the heterocyclyl ring has five or six ring atoms. Examples of heterocyclyl groups include, but are not limited to, aziridinyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholino, tetrahydropyranyl, tetrahydrofuryl, and thiomorphilino. The said ring may be optionally substituted by one or more substituents independently selected from d. 6alkyl and oxy.
As used herein, the terms "fused bicyclic ring system" and "fused bicyclyl" refer to a ring system comprising two five- to seven-membered saturated or unsaturated rings, the ring system containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, each ring has five or six ring atoms. Examples of suitable fused bicyclic rings include, but are not limited to, naphthyl, indolyl, indolinyl, benzothienyl quinolyl, isoquinolyl, tetrahydroquinolyl, benzodioxanyl, indanyl and tetrahydronaphthyl. Each ring may be optionally substituted with one or more substituents independently selected from halogen, d^alkyl, oxy, -(CH2)PNR10R11, - CO(CH2)pNR10R11, and imidazolyl. Particularly preferred substituents are chlorine, imidazolyl and -CH2-N(CH3)2.
As used herein, the terms "halogen" or "halo" refer to the elements fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine. A particularly preferred halogen is fluorine.
As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.
As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water.
Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism).
The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention. The present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted. Likewise, it is understood that compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.
Salts of the compounds of the present invention are also encompassed within the scope of the invention and may, for example, comprise acid addition salts resulting from reaction of an acid with a nitrogen atom present in a compound of formula (I).
Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Representative salts include the following salts: Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Calcium Edetate, Camsylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate,
Gluconate, Glutamate, Glycollylarsanilate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isethionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Monopotassium Maleate, Mucate, Napsylate, Nitrate, N- methylglucamine, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate,
Phosphate/diphosphate, Polygalacturonate, Potassium, Salicylate, Sodium, Stearate, Subacetate, Succinate, Tannate, Tartrate, Teoclate, Tosylate, Triethiodide, Trimethylammonium and Valerate. Other salts which are not pharmaceutically acceptable may be useful in the preparation of compounds of this invention and these form a further aspect of the invention.
The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.
For example, a general method (A) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 1 below.
Figure imgf000009_0001
(III)
( i)
Figure imgf000009_0002
Scheme 1 (i) Di-t-butyldicarbonate, Et3N, DCM
(ii) (4-Methoxycarbonylphenyl)boronic acid, (Ph3P) Pd, CsCO3, DME
(iii) LiOH, THF, H2O
(iv) R1(CH2)nX(CH2)mNR2H, HATU, DIPEA, THF
(v) TFA, DCM
(vi) R4COOH, HATU, DIPEA, DMF
For example, a general method (B) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 2 below.
Figure imgf000010_0001
(iϋ) (iv)
Figure imgf000010_0002
Scheme 2 (i) (4-Methoxycarbonylphenyl)boronic acid, (Ph3P) Pd, CsCO3, DME
(ii) R COOH, HATU, DIPEA, DMF (iii) LiOH, THF, H2O (iv) R1(CH2)mX(CH2)„N R2H, HATU, DIPEA, THF
For example, a general method (C) for preparing the compounds of Formula (I) wherein R is
Figure imgf000011_0001
comprises the reactions set out in Scheme 3 below.
Figure imgf000011_0002
Scheme 3 (i) Et3N, DCM
(ii) LiOH, THF, H2O
(iii) R'R"NH
(iv) R1(CH2)nX(CH2)mNR2H, HATU, DIPEA, THF
For example, a general method (D) for preparing the compounds of Formula (I) wherein R4 is
Figure imgf000012_0001
comprises the reactions set out in Scheme 4 below.
Figure imgf000012_0002
Scheme 4 (i) Et3N, DCM (ii) R'R"NH (iii) LiOH, THF, H2O (iv) R1(CH2)nX(CH2)mNR2H, HATU, DIPEA, THF
For example, a general method (E) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 5 below.
Figure imgf000013_0001
Scheme 5
(i) (4-Methoxycarbonylphenyl)boronic acid, (Ph3P)4Pd, CsCO3, DME (ii) LiOH, THF, H2O
(iii) R1(CH2)mX(CH2)nNR2H, HATU, DIPEA, THF (iv) R4COCI, Et3N, DCM
Thus, according to the invention there is provided a process for preparing a compound of formula (I) which comprises:
(a) reacting a compound of formula (XII)
Figure imgf000014_0001
(XII)
wherein R1, R2, U, V, W, X, Y, m, n and t are as defined above, with a compound of formula (XIII)
R CO2H
(XIII) wherein R4 is as defined above, under amide forming conditions (if desired, the acid compound (XIII) may be converted to an activated form of the acid, for example the acid chloride, and then the activated acid thus formed reacted with the amine compound (XII)); or
(b) reacting a compound of formula (XIV)
Figure imgf000015_0001
(XIV) wherein R3, U, V, W, Y and t are as defined above, with a compound of formula (XV)
RHCH2)mX(CH2)nNR2H
(XV)
wherein R1 , R2, X, m and n are as defined above, under amide forming conditions.
Suitable amide forming conditions are well known in the art and include treating a solution of the acid, in for example THF, with an amine in the presence of, for example, HATU and DIPEA.
Whilst it is possible for the compounds, salts or solvates of the present invention to be administered as the new chemical, the compounds of formula (I) and their pharmaceutically acceptable salts and solvates are conveniently administered in the form of pharmaceutical compositions. Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
The compounds of formula (I) and their pharmaceutically acceptable salts and solvates may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable salts and solvates. A particularly preferred method of administration, and corresponding formulation, is oral administration.
For oral administration, the pharmaceutical composition may take the form of, and be administered as, for example, tablets (including sub-lingual tablets) and capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, emulsions, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present. Capsules can be made by preparing a powder mixture as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or saccharin, and the like can also be added.
Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like. The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
The compounds of the present invention can also be administered in the form of liposome emulsion delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
The present invention includes pharmaceutical compositions containing 0.1 to 99.5%, more particularly, 0.5 to 90% of a compound of the formula (I) in combination with a pharmaceutically acceptable carrier.
Likewise, the composition may also be administered in nasal, ophthalmic, otic, rectal, topical, intravenous (both bolus and infusion), intraperitoneal, intraarticular, subcutaneous or intramuscular, inhalation or insufflation form, all using forms well known to those of ordinary skill in the pharmaceutical arts. For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.
For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravasculariy or subcutaneously). The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative. Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.
The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
Alternatively the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 μg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, dose is from about 100 μg/kg to about 5 mg/kg body weight, daily. For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0. 1 mg/kg to 10 mg/kg and typically around 1 mg/kg. It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The effectiveness of a selected actual dose can readily be determined, for example, by measuring clinical symptoms or standard anti-inflammatory indicia after administration of the selected dose.
The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. For conditions or disease states as are treated by the present invention, maintaining consistent daily levels in a subject over an extended period of time, e.g., in a maintenance regime, can be particularly beneficial.
In another aspect, the present invention provides a compound of formula (I) or a salt or solvate thereof, for use in therapy.
The compounds of the present invention are generally inhibitors of the serine/threonine kinase p38 and are therefore also inhibitors of cytokine production which is mediated by p38 kinase. Within the meaning of the term "inhibitors of the serine/threonine kinase p38" are included those compounds that interfere with the ability of p38 to transfer a phosphate group from ATP to a protein substrate according to the assay described below.
It will be appreciated that the compounds of the invention may be selective for one or more of the isoforms of p38, for example p38α, p38β, p38γ and/or p38δ. In one embodiment, the compounds of the invention selectively inhibit the p38α isoform. In another embodiment, the compounds of the invention selectively inhibit the p38β isoform. In a further embodiment, the compounds of the invention selectively inhibit the p38α and p38β isoforms. Assays for determining the selectivity of compounds for the p38 isoforms are described in, for example, WO 99/61426, WO 00/71535 and WO
02/46158.
It is known that p38 kinase activity can be elevated (locally or throughout the body), p38 kinase can be incorrectly temporally active or expressed, p38 kinase can be expressed or active in an inappropriate location, p38 kinase can be constitutively expressed, or p38 kinase expression can be erratic; similarly, cytokine production mediated by p38 kinase activity can be occurring at inappropriate times, inappropriate locations, or it can occur at detrimentally high levels.
Accordingly, the present invention provides a method for the treatment of a condition or disease state mediated by p38 kinase activity, or mediated by cytokines produced by the activity of p38 kinase, in a subject which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.
The present invention also provides a method of inhibiting cytokine production which is mediated by p38 kinase activity in a subject, e.g. a human, which comprises administering to said subject in need of cytokine production inhibition a therapeutic, or cytokine-inhibiting, amount of a compound of the present invention. The compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.
The present invention treats these conditions by providing a therapeutically effective amount of a compound of this invention. By "therapeutically effective amount" is meant a symptom-alleviating or symptom-reducing amount, a cytokine-reducing amount, a cytokine-inhibiting amount, a kinase-regulating amount and/or a kinase- inhibiting amount of a compound. Such amounts can be readily determined by standard methods, such as by measuring cytokine levels or observing alleviation of clinical symptoms. For example, the clinician can monitor accepted measurement scores for anti-inflammatory treatments.
The compounds of the present invention can be administered to any subject in need of inhibition or regulation of p38 kinase or in need of inhibition or regulation of p38 mediated cytokine production. In particular, the compounds may be administered to mammals. Such mammals can include, for example, horses, cows, sheep, pigs, mice, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably, humans.
Thus, the present invention provides methods of treating or reducing symptoms in a human or animal subject suffering from, for example, rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs. host reaction, allograft rejections, sepsis, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to aquired immune deficiency syndrome (AIDS), malaria, leprosy, infectious arthritis, leishmaniasis, Lyme disease, glomerulonephritis, gout, psoriatic arthritis, Reiter's syndrome, traumatic arthritis, rubella arthritis, Crohn's disease, ulcerative colitis, acute synovitis, gouty arthritis, spondylitis, and non articular inflammatory conditions, for example, herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendonitis, tenosynovitis, fibromyalgic syndrome and other inflammatory conditions associated with ligamentous sprain and regional musculoskeletal strain, pain, for example that associated with inflammation and/or trauma, osteopetrosis, restenosis, thrombosis, angiogenesis, cancer including breast cancer, colon cancer, lung cancer or prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula(l) or a pharmaceutically acceptable salt or solvate thereof.
A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, neurodegenerative disease,
Alzheimer's disease, Parkinson's disease and epilepsy which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
A further aspect of the invention provides a method of treatment of a human or animal subject suffering from any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by p38 kinase activity. A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs. host reaction, allograft rejections, sepsis, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to aquired immune deficiency syndrome (AIDS), malaria, leprosy, infectious arthritis, leishmaniasis, Lyme disease, glomerulonephritis, gout, psoriatic arthritis, Reiter's syndrome, traumatic arthritis, rubella arthritis, Crohn's disease, ulcerative colitis, acute synovitis, gouty arthritis, spondylitis, and non articular inflammatory conditions, for example, herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendonitis, tenosynovitis, fibromyalgic syndrome and other inflammatory conditions associated with ligamentous sprain and regional musculoskeletal strain, pain, for example that associated with inflammation and/or trauma, osteopetrosis, restenosis, thrombosis, angiogenesis, and cancer including breast cancer, colon cancer, lung cancer or prostatic cancer.
A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy, and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis,
Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease and epilepsy.
A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain. The compounds of formula (I) and their salts, solvates and physiologically functional salts and solvates may be employed alone or in combination with other therapeutic agents for the treatment of the above-mentioned conditions. In particular, in rheumatoid arthritis therapy, combination with other chemotherapeutic or antibody agents is envisaged. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one other pharmaceutically active agent. The compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, this may occur separately or sequentially in any order. The amounts of the compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. Examples of other pharmaceutically active agents which may be employed in combination with compounds of formula (I) and their salts and solvates for rheumatoid arthritis therapy include: immunosuppresants such as amtolmetin guacil, mizoribine and rimexolone; anti-TNFα agents such as etanercept, infliximab, diacerein; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subreum; interleukin 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as NRD-101 (Aventis); interleukin 1 receptor antagonists such as anakinra; CD8 antagonists such as amiprilose hydrochloride; beta amyloid precursor protein antagonists such as reumacon; matrix metalloprotease inhibitors such as cipemastat and other disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, sulphasalazine, cyclosporin A, hydroxychoroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine.
Examples
The following examples are illustrative embodiments of the invention, not limiting the scope of the invention in any way. Reagents are commercially available or are prepared according to procedures in the literature. LCMS was conducted on a column (3.3cm x 4.6mm ID, 3um ABZ+PLUS), at a Flow Rate of 3ml/min, Injection Volume of 5μl, at room temperature and UV Detection Range at 215 to 330nm.
Example 1: N-(6-Methyl-4'-{f3-(4-methylpiperazin-1 -yl)propylamino1carbonyl)-1.1 '- biphenyl-3-yl)-2-pyrrolidin-1-ylisonicotinamide a) 2'-Methyl-5'-[(2-pyrrolidin-1 -ylisonicotinoyl)amino]-1 , 1 '-biphenyl-4-carboxylic acid (40mg, O.lmmol), HATU (38mg, O.lmmol), HOBT (13mg, O.lmmol), DIPEA (52μl), and 1-(3-aminomethyl)-4-methylpiperazine (19mg, 0.12mmol) were mixed in DMF (1ml) and stirred at room temperature for 18h. The solvent was evaporated under vacuum and the residue partitioned between DCM (5ml) and aqueous sodium carbonate (1M, 5ml). The organic phase was applied to a silica gel flash column and eluted with toluene/methanol (8:2, 7:3, 6:4), which after evaporation of the solvents under vacuum gave N-(6-methyl-4'-{[3-(4-methylpiperazin-1-yl)propylamino]carbonyl}-1,1'-biphenyl-3- yl)-2-pyrrolidin-1-ylisonicotinamide (48mg, 89%). NMR; δH [2H6] - DMSO 10.51,(1 H, s), 8.68,(1H, t), 8.17,(1H, d), 7.93,(2H, d), 7.76,(1 H, dd), 7.72,(1H, d), 7.42,(2H, d), 7.28,(1H, d), 7.00,(1H, d), 6.95,(1H, d), 3.43,(4H, m), 3.29,(2H, q), 2.49-2.32,(1 OH, m), 2.21-2.19,(6H, m), 1.94,(4H, m), 1.70,(2H, m). LCMS: retention time 2.13min, MH+541.
b) 2'-Methyl-5'-[(2-pyrrolidin-1 -ylisonicotinoyl)amino]-1 , 1 '-biphenyl-4-carboxylic acid
5'-[(2-Chloroisonicotinoyl)amino]-2'-methyl-1 , 1 '-biphenyl-4-carboxylic acid (600mg, 1.64mmol) and pyrrolidine (0.6ml) were heated in a sealed tube at 90°C for 5h. The excess pyrrolidine was evaporated under vacuum and the residue purified by flash chromatography (silica) eluting with DCM/ethanol/ammonia (20:8:1). The solvents were evaporated under vacuum to give 2'-methyl-5'-[(2-pyrrolidin-1-ylisonicotinoyl)amino]-
1 ,1'-biphenyl-4-carboxylic acid (546mg, 83%). LCMS: retention time 2.74min, MH+402.
c) 5'-[(2-Chloroisonicotinoyl)amino]-2'-methyl-1 , 1 '-biphenyl-4-carboxylic acid Methyl 5'-[(2-chloroisonicotinoyl)amino]-2'-methyl-1 , 1 '-biphenyl-4-carboxylate (1.63g, 4.28mmol) and lithium hydroxide monohydrate (376mg, Θ.Ommol) were mixed in water
(5ml) and THF (10ml)and stirred at room temperature for 90h. The pH was adjusted to pH3 by addition of hydrochloric acid (2N) and the mixture extracted with ethyl acetate (3x 50ml). The combined extracts were washed with water (75ml), brine (75ml), dried (magnesium sulphate)and concentrated under vacuum. The residue was purified by flash column chromatography on silica eluting with DCM/ethanol/ammonia (30:8:1 then
20:8:1). The solvents were evaporated under vacuum to give 5'-[(2- chloroisonicotinoyl)amino]-2'-methyl-1 ,1'-biphenyl-4-carboxylic acid (1.15g, 73%). LCMS: retention time 3.53min, MH+367.
d) Methyl 5'-[(2-chloroisonicotinoyl)amino]-2'-methyl-1 ,1'-biphenyl-4-carboxylate 2-Chloropyridine-4-carbonyl chloride (1.58g, 9.0mmol) in DCM (10ml) was added dropwise to a solution of methyl 5'-amino-2'-methyl-1,1'-biphenyl-4-carboxylate (1.81g, 7.5mmol) and triethylamine (3.13ml, 22.5mmol) in DCM (10ml) at 0°C. The reaction was stirred at room temperature for 20h, the solvent evaporated under vacuum and the residue partitioned between ethyl acetate (50ml) and saturated aqueous sodium bicarbonate (50ml). The aqueous was extracted with ethyl acetate (50ml) and the combined organic phases washed with brine (50ml), dried (magnesium sulphate) and the solvent evaporated under vacuum. The residue was purified by flash column chromatography on silica eluting with DCM/ethanol/ammonia (300:8:1). The solvents were evaporated under vacuum to give methyl 5'-[(2-chloroisonicotinoyl)amino]-2'- methyl-1,1'-biphenyl-4-carboxylate (1.73g, 61%). LCMS: retention time 3.69min, MH+381.
e) Methyl 5'-amino-2'-methyl-1 , 1 '-biphenyl-4-carboxylate 3-Bromo-4-methylaniline (744mg, 4.0mmol), (4-methoxycarbonylphenyl)boronic acid
(864mg, 4.8mmol), tetrakis(triphenylphosphine)palladium (100mg, 0.087mmo.) and caesium carbonate (2.4g, 7.37mmol) were mixed in DME (30ml) and heated at 90°C for 20h. The reaction was absorbed onto silica applied to a silica SPE (10g) and eluted with ethyl acetate/cyclohexane (0-100% ethyl acetate). The solvent was evaporated from the product fractions under vacuum to give methyl 5'-amino-2'-methyl-1,1'- biphenyl-4-carboxylate (500mg, 43%). NMR; δH CDCI3 8.07,(2H, d), 7.38,(2H, d), 7.07,(1 H, d), 6.67,(1 H, dd), 6.60,(1 H, d), 3.94,(3H, s), 2.14,(3H, s).
Example 2: N-(6-Methyl-4'-r(3-morpholin-1-ylpropylamino)carbonvn-1 ,1'-biphenyl- 3-yl}-2-pyrrolidin-1-ylisonicotinamide
2'-Methyl-5'-[(2-pyrrolidin-1-ylisonicotinoyl)amino]-1 ,1'-biphenyl-4-carboxylic acid (40mg, O.lmmol), HATU (38mg, O.lmmol), HOBT (13mg, O.lmmol), DIPEA (52μl), and 3- morpholin-1-ylpropylamine (17mg, 0.12mmol) were mixed in DMF (1ml) and stirred at room temperature for 18h. The solvent was evaporated under vacuum and the residue partitioned between DCM (5ml) and aqueous sodium carbonate (1M, 5ml). The organic phase was applied to a silica gel flash column and eluted with toluene/methanol (8:2), which after evaporation of the solvents under vacuum gave N-{6-methyl-4'-[(3- morpholin-1-ylpropylamino)carbonyl]-1,1'-biphenyl-3-yl}-2-pyrrolidin-1 -ylisonicotinamide (19mg, 36%). NMR; δH [2H6] - DMSO 10.27,(1H, s), 8.54,(1H, t), 8.19,(1H, d), 7.91, (2H, d), 7.70,(1 H, dd), 7.65,(1 H, d), 7.44,(2H, d), 7.29,(1 H, d), 6.96,(1 H, d),
6.85,(1 H, d), 3.56,(4H, m), 3.43,(4H, m), 3.31, (2H, m), 2.34,(6H, m), 2.20,(3H, s), 1.95,(4H, m), 1.69,(2H, m). MS: MH+ 528.
Example 3: N-|4'-r(3-lmidazol-1-ylpropylamino)carbonvn-6-methyl-1,1'-biphenyl-3- yl>-2-pyrrolidin-1 -ylisonicotinamide 2'-Methyl-5'-[(2-pyrrolidin-1-ylisonicotinoyl)amino]-1,1'-biphenyl-4-carboxylic acid (40mg, O.lmmol), HATU (38mg, O.lmmol), HOBT (13mg, O.lmmol), DIPEA (52μl), and 1-(3- aminopropyl)imidazole (15mg, 0.12mmol) were mixed in DMF (1ml) and stirred at room temperature for 18hours. The solvent was evaporated under vacuum and the residue partitioned between DCM (5ml) and aqueous sodium carbonate (1M, 5ml). The organic phase was applied to a silica gel flash column and eluted with toluene/methanol (8:2), which after evaporation of the solvents under vacuum gave N-{4'-[(3-imidazol-1- ylpropylamino)carbonyl]-6-methyl-1,1'-biphenyl-3-yl}-2-pyrrolidin-1 -ylisonicotinamide (12mg, 24%). NMR; δH [2H6] - DMSO 10.31, (1H, s), 8.60,(1H, t), 8.19,(1H, d), 7.93,(2H, d), 7.71 , (1 H, dd), 7.67,(2H, m), 7.45,(2H, d), 7.30,(1 H, d), 7.22,(1 H, s),
6.96,(1 H, s), 6.86,(1 H, s), 4.03,(2H, t), 3.43,(4H, m), 3.26,(2H, q), 2.20,(3H, s), 1.99- 1.93,(6H, m). LCMS: retention time 2.24min, MH+509.
Example 4: N-(6-Methyl-4'-f(4-methylpiperazin-1-yl)carbonyll-1.1 '-biphenyl-3-yl)-2- pyrrolidin-1 -ylisonicotinamide
2'-Methyl-5'-[(2-pyrrolidin-1 -ylisonicotinoyl)amino]-1 , 1 '-biphenyl-4-carboxylic acid (40mg, O.lmmol), HATU (38mg, O.lmmol), HOBT (13mg, O.lmmol), DIPEA (52μl), and 1- methylpiperazine (15mg, 0.12mmol) were mixed in DMF (1ml) and stirred at room temperature for 18h. The solvent was evaporated under vacuum and the residue partitioned between DCM (5ml) and aqueous sodium carbonate (1M, 5ml). The organic phase was applied to a silica gel flash column and eluted with DCM/ethanol/ammonia (100:8:1 then 40:8:1), which after evaporation of the solvents under vacuum gave N-{6- methyl-4'-[(4-methylpiperazin-1 -yl)carbonyl]-1 , 1 '-biphenyl-3-yl}-2-pyrrolidin-1 - ylisonicotinamide (14mg, 29%). NMR; δH [2H6] - DMSO 10.26,(1H, s), 8.19,(1H, d), 7.69-7.67,(2H, m), 7.47-7.41, (4H, m), 7.29,(1H, d), 6.96,(1H, d), 6.86,(1H, s), 3.59,(2H, b), 3.43,(4H, m), 2.33,(6H, b), 2.21, (3H, s), 2.21, (3H, s), 1.95,(4H, m). MS: MH+484.
Example 5: N-(4'-(f3-(4-Methylpiperazin-1 -yl)propylamino1carbonyl)-6-methyl-1 , 1 '- biphenyl-3-yl)-3-furamide a) 5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (50mg, 0.156mmol),
TBTU (60mg, 0.186mmol), 1-(3-aminopropyl)-4-methylpiperazine (25mg, 0.156mmol) and DIPEA (81 μl, 0.467mmol) in DMF (1ml) were stirred at room temperature for 2h. The DMF was evaporated under vacuum and the residue dissolved in chloroform and filtered through an aminopropyl SPE (3g). The filtrate was purified by flash chromatography on silica, eluting with DCM/ethanol/ammonia (110:8:1), which after evaporation of the solvents under vacuum gave N-(4'-{[3-(4-methylpiperazin-1- yl)propylamino]carbonyl}-6-methyl-1,1'-biphenyl-3-yl)-3-furamide (12mg, 17%). NMR; δH [2H6] - DMSO 9.91, (1H, s), 8.55,(1 H, t), 8.35,(1 H, s), 7.90,(2H, d), 7.78,(1 H, t), 7.66,(1 H, dd), 7.59,(1 H, d), 7.43,(2H, d), 7.27,(1 H, d), 6.98,(1 H, m), 3.29,(2H, m), 2.48- 2.20,(10H, m), 2.19,(3H, s), 2.13,(3H, s), 1.68,(2H, m). LCMS: retention time 2.37min, MH+461.
b) 5'-(3-Furoylamino)-2'-methyl-1 , 1 '-biphenyl-4-carboxylic acid Methyl 5'-(3-furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylate (980mg, 2.9mmol) and lithium hydroxide monohydrate (256mg, 6.1mmol) in THF (12ml) and water (6ml) were heated at 75°C for 18h. The THF was evaporated under vacuum and the aqueous adjusted to pH3 with hydrochloric acid (1M). The precipitate which formed was filtered off, washed with ether and dried under vacuum to give 5'-(3-furoylamino)-2'-methyl-1,1'- biphenyl-4-carboxylic acid (720mg, 77%). LCMS: retention time 3.33min, MH+322.
c) Methyl 5'-(3-furoylamino)-2'-methyl-1 ,1 '-biphenyl-4-carboxylate
3-Furoic acid (557mg, 4.97mmol), HATU (1.89g, 4.97mmol), HBTU (560mg, 4.14mmol), methyl 5'-amino-2'-methyl-1 ,1'-biphenyl-4-carboxylate (1.0g, 4.14mmol) and DIPEA (2.17ml, 12.43mmol) were mixed in DMF (5ml) and the reaction stirred at room temperature for 18h. The DMF was evaporated under vacuum, the residue partitioned between DCM (50ml) and aqueous sodium carbonate (1M, 50ml) and the aqueous extracted with DCM (2x 30ml). The combined organics were washed with brine (75ml), dried (magnesium sulphate) and concentrated under vacuum. The residue was purified on a silica flash column eluting with DCM/ethanol/ammonia (500:8:1), which after evaporation of the solvents under vacuum gave methyl 5'-(3-furoylamino)-2'-methyl- 1,1'-biphenyl-4-carboxylate (800mg, 58%). LCMS: retention time 3.41 min, MH+336.
Example 6: N-(6-Methyl-4'-|f(3-morphlin-4-ylmethylbenzyl)aminolcarbonyl>-1.1 '- biphenyl-3-yl)-3-furamide a) 5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (50mg, 0.156mmol), 3-(morpholin-4-ylmethyl)benzylamine (32mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21 mg, 0.156mmol) and DIPEA (27μl, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried (magnesium sulphate). The solvent was evaporated under vacuum and the residue chromatographed on a silica flash column eluting with DCM/methanol/triethylamine (96:2:2). Concentration of the product fractions under vacuum gave N-(6-methyl-4'-{[(3-morphlin-4-ylmethylbenzyl)amino]carbonyl}-1 , 1 '- biphenyl-3-yl)-3-furamide (51 mg, 81%). NMR; δH [2H6] - DMSO 9.92,(1 H, s), 9.11 , (1 H, t), 8.35,(1 H, s), 7.97,(2H, d), 7.78,(1 H, t), 7.66,(1H, dd), 7.60,(1H, d),
7.46,(2H, d), 7.28,(3H, m), 7.22,(1 H, d), 7.17,(1 H, d), 6.98,(1H, m), 4.50,(2H, d), 3.54,(4H, m), 3.43,(2H, s), 2.33,(4H, m), 2.19,(3H, s). LCMS: retention time 2.40min, MH+510.
b) 5'-(3-Furoylamino)-2'-methyl-1 , 1 '-biphenyl-4-carboxylic acid Methyl 5'-(3-furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylate (980mg, 2.9mmol) and lithium hydroxide monohydrate (256mg, 6.1mmol) in THF (12ml) and water (6ml) were heated at 75°C for 18h. The THF was evaporated under vacuum and the aqueous adjusted to pH3 with hydrochloric acid (1M). The precipitate which formed was filtered off, washed with ether and dried under vacuum to give 5'-(3-furoylamino)-2'-methyl-1,1'- biphenyl-4-carboxylic acid (720mg, 77%). LCMS: retention time 3.33min, MH+322.
c) Methyl 5'-(3-furoylamino)-2'-methyl-1 , 1 '-biphenyl-4-carboxylate
3-Furoic acid (557mg, 4.97mmol), HATU (1.89g, 4.97mmol), HBTU (560mg, 4.14mmol), methyl 5'-amino-2'-methyl-1,1'-biphenyl-4-carboxylate (1.0g, 4.14mmol) and DIPEA
(2.17ml, 12.43mmol) were mixed in DMF (5ml) and the reaction stirred at room temperature for 18h. The DMF was evaporated under vacuum, the residue partitioned between DCM (50ml) and aqueous sodium carbonate (1M, 50ml) and the aqueous extracted with DCM (2x 30ml). The combined organics were washed with brine (75ml), dried (magnesium sulphate) and concentrated under vacuum. The residue was purified on a silica flash column eluting with DCM/ethanol/ammonia (500:8:1), which after evaporation of the solvents under vacuum gave methyl 5'-(3-furoylamino)-2'-methyl- 1,1'-biphenyl-4-carboxylate (800mg, 58%). LCMS: retention time 3.41 min, MH+336.
Example 7: N-r4'-((r(1-t-Butyloxycarbonylpiperidin-4-yl)methvnamino>carbonyl)-6- methyl-1 , 1 '-biphenyl-3-vπ-3-furamide 5'-(3-Furoylamino)-2'-methyl-1 , 1 '-biphenyl-4- carboxylic acid (50mg, 0.156mmol), 1-t-butyloxycarbonyl-4-aminomethylpiperidine (33.3mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21mg, 0.156mmol) and DIPEA (27μl, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried
(magnesium sulphate). The solvent was evaporated under vacuum and the residue chromatographed on a silica flash column eluting with DCM/methanol/triethylamine (96:2:2). Concentration of the product fractions under vacuum N-[4'-({[(1-t- butyloxycarbonylpiperidin-4-yl)methyl]amino}carbonyl)-6-methyl-1 , 1 '-biphenyl-3-yl]-3- furamide (45mg, 56%). NMR; δH [2H6] - DMSO 9.91,(1 H, s), 8.56,(1 H, t), 8.35,(1 H, s),
7.91, (2H, d), 7.78,(1 H, t), 7.66,(1 H, dd), 7.59,(1 H, d), 7.43,(2H, d), 7.27,(1 H, d), 6.98,(1 H, m), 3.93,(2H, m), 3.17,(2H, t), 2.68,(2H, b), 2.19,(3H, s), 1.74,(1H, b), 1.67,(2H, m), 1.38,(9H, s), 1.03,(2H, m). LCMS: retention time 3.50min, [MH-BOC]+ 418.
Example 8: N-(6-Methyl-4'-ff2-(4-methylpiperazin-1-yl)anilino1carbonyl)>-1.1'- biphenyl-3-yl)-3-furamide
5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (50mg, 0.156mmol), 2-(4- methylpiperazin-1-yl)aniline (29.8mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21mg, 0.156mmol) and DIPEA (27μl, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried (magnesium sulphate). The solvent was evaporated under vacuum and the residue chromatographed on a silica flash column eluting with DCM/methanol/triethylamine (96:2:2). Concentration of the product fractions under vacuum N-(6-methyl-4'-{[2-(4-methylpiperazin-1-yl)anilino]carbonyl)}-1,1'-biphenyl-3-yl)- 3-furamide (40mg, 52%). NMR; δH [2H6] - DMSO 9.93,(1 H, s), 9.63,(1 H, s), 8.35,(1 H, s), 8.15,(1H, m), 8.02,(2H, d), 7.79,(1H, t), 7.68,(1H, dd), 7.65,(1 H, d), 7.57,(2H, d), 7.31-7.27,(2H, m), 7.16-7.14,(2H, m), 6.98,(1 H, m), 2.88,(4H, t), 2.51, (4H, m), 2.23,(6H, s). LCMS: retention time 2.68min, MH+495.
Example 9: N-(6-Methyl-4'-ff2-(4-methylpiperazin-1-ylmethyl)anilino1carbonyl)-
1.1 '-biphenyl-3-yl)-3-furamide
5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (50mg, 0.156mmol), 2-(4- methylpiperazin-1-ylmethyl)aniline (32.0mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21mg, 0.156mmol) and DIPEA (27μl, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried (magnesium sulphate). The solvent was evaporated under vacuum and the residue chromatographed on a silica flash column eluting with DCM/methanol/triethylamine (96:2:2). Concentration of the product fractions under vacuum N-(6-methyl-4'-{[2-(4-methylpiperazin-1 -ylmethyl)anilino]carbonyl}-1 , 1 '- biphenyl-3-yl)-3-furamide (63mg, 79%). NMR; δH [2H6] - DMSO includes 11.56,(1 H, s), 9.94,(1 H, s), 8.36-8.34,(2H, m), 8.02,(2H, d), 7.78,(1 H, t), 7.68,(1 H, dd), 7.64,(1 H, d), 7.54,(2H, d), 7.35-7.25,(3H, m), 7.06,(1 H, m), 6.98,(1 H, m), 3.73,(2H, s), 2.22,(3H, s), 2.11,(3H, s). LCMS: retention time 2.60min, MH+509.
Example 10: N-(6-Methyl-4'-ff3-(4-methylpiperazin-1-yl)anilinolcarbonyl}-1.1'- biphenyl-3-yl)-3-furamide
5'-(3-Furoylamino)-2'-methyl-1.1'-biphenyl-4-carboxylic acid (50mg. 0.156mmol), 3-(4- methylpiperazin-1-yl)aniline (29.8mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21mg, 0.156mmol) and DIPEA (27μl, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried (magnesium sulphate). The solvent was evaporated under vacuum and the residue chromatographed on a silica flash column eluting with DCM/methanol/triethylamine (96:2:2). Concentration of the product fractions under vacuum N-(6-methyl-4'-{[3-(4-methylpiperazin-1 -yl)anilino]carbonyl}-1 , 1 '-biphenyl-3-yl)-
3-furamide (59.5mg, 77%). NMR; δH [2H6] - DMSO 10.13,(1H, s), 9.93,(1 H, s), 8.36,(1H, s), 8.02,(2H, d), 7.78,(1H, t), 7.68,(1H, dd), 7.63,(1H, d), 7.51, (2H, d), 7.43,(1H, m), 7.30-7.26,(2H, m), 7.17,(1H, t), 6.99,(1 H, m), 6.70,(1H, dd), 3.12,(4H, m), 2.46,(4H, m), 2.22,(6H, s). LCMS: retention time 2.43min, MH+495. Example 11: N-(6-Methyl-4'-(r2-(2-morpholin-4-ylethyl)anilinolcarbonyl)-1.1 '- biphenyl-3-yl)-3-furamide a) 5'-(3-Furoylamino)-2'-methyl-1 ,1'-biphenyl-4-carboxylic acid (50mg, 0.156mmol), 2-(2-morpholin-4-ylethyl)aniline (32.2mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21mg, 0.156mmol) and DIPEA (27μl, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried (magnesium sulphate). The solvent was evaporated under vacuum and the residue chromatographed on a silica flash column eluting with DCM/methanol/triethylamine (96:2:2). Concentration of the product fractions under vacuum N-(6-methyl-4'-{[2-(2-morpholin-4-ylethyl)anilino]carbonyl}-1 , 1 '-biphenyl-3-yl)-3- furamide (59.2mg, 74%). NMR; δH [2H6] - DMSO 10.08,(1 H, s), 9.94,(1 H, s), 8.36,(1 H, s), 8.04,(2H, s), 7.79,(1 H, t), 7.68,(1 H, dd), 7.63,(1 H, d), 7.52,(2H, d), 7.38-7.18,(4H, m), 6.98,(1 H, m), 3.47,(4H, m), 2.80,(2H, t), 2.48,(2H, m), 2.34,(4H, m), 2.22,(3H, s). LCMS: retention time 2.60min, MH+510.
b) 2-(2-Morpholin-4-ylethyl)aniline
4-[(2-Nitrophenyl)ethyl]morpholine (11.4g, 40mmol) and palladium on carbon (10%, 500mg) in ethanol (200ml) were hydrogenated under 1 Atm. of hydrogen at room temperature for 3h. The reaction was filtered through hyflo and the filtrate reduced to dryness under vacuum. The residue was recrystallised from toluene/hexane to give 2- (2-morpholin-4-y!ethyl)aniline (6.375g). Microanalysis: calculated C 69.87, H 8.80, N 13.58; found C 69.80, H 8.95, N 13.60.
c) 4-[(2-Nitrophenyl)ethyl]morpholine To a solution of 4-[(2-nitrophenyl)acetyl]morpholine (10g, 40mmol) in THF (250ml) was added borane.THF (1.0M, 60ml, 60mmol) and the mixture heated at reflux for 1h. A further portion of borane.THF (1.0M, 80ml, δOmmol) was added and reflux continued for 1 h. The cooled reaction was quenched by addition of hydrochloric acid (concentrated, 8ml) and left at room temperature for 18h. The mixture was concentrated under vacuum, basified with aqueous sodium hydroxide (2N) and extracted with ether (3x
100ml). The combined extracts were dried (magnesium sulphate) and the solvent evaporated under vacuum to give a crude sample of 4-[(2-nitrophenyl)ethyl]morpholine (11.42g), which was used without further purification. Microanalysis: calculated C 61.007, H 6.83, N 11.86; found C 62.38, H 8.02, N 9.54.
Example 12: N-(4'-(r(3-lmidazol-1-ylpropyl)aminolcarbonyl>-6-methyl-1.1'-biphenyl-
3-yl)-3-furamide
5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (50mg, 0.156mmol), 1-(3- aminopropyl)imidazole (19.5mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21mg, 0.156mmol) and DIPEA (27μl, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried (magnesium sulphate). The solvent was evaporated under vacuum and the residue chromatographed on a silica flash column eluting with DCM/methanol/triethylamine (96:2:2). Concentration of the product fractions under vacuum N-(4'-{[(3-imidazol-1-ylpropyl)amino]carbonyl}-6-methyl-1,1'-biphenyl-3-yl)-3- furamide (44.1 mg, 66%). NMR; δH [2H6] - DMSO 9.92,(1 H, s), 8.58,(1 H, t), 8.35,(1 H, s), 7.92,(2H, d), 7.78,(1 H, t), 7.67-7.65,(2H, m), 7.60,(1 H, d), 7.44,(2H, d), 7.27,(1 H, d), 7.22,(1H, m), 6.98,(1 H, m), 6.89,(1H, m), 4.03,(2H, t), 3.26,(2H, q), 2.19,(3H, s), 1.97,(2H, m). LCMS: retention time 2.31 min, MH+429.
Example 13: N-(6-Methyl-4' f(3-morpholin-4-ylpropyl)aminolcarbonyl>-1.1 '- biphenyl-3-yl)-3-furamide
5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (50mg, 0.156mmol), 4-(3- aminopropyl)morpholine (22.5mg, 0.156mmol), HATU (59.2mg, 0.156mmol), HOBT (21 mg, 0.156mmol) and DIPEA (27μl, 0.156mmol) in DMF (2ml) were stirred at room temperature for 18h. The reaction was diluted with ethyl acetate (150ml), washed with water (2x 30ml) and dried (magnesium sulphate). The solvent was evaporated under vacuum and the residue chromatographed on a silica flash column eluting with DCM/methanol/triethylamine (96:2:2). Concentration of the product fractions under vacuum N-(6-methyl-4'-{[(3-morpholin-4-ylpropyl)amino]carbonyl}-1 ,1 '-biphenyl-3-yl)-3- furamide (59.5mg, 83%). NMR; δH [2H6] - DMSO 9.94,(1 H, s), 8.55,(1 H, t), 8.36,(1 H, s), 7.90,(2H, d), 7.78,(1 H, t), 7.67,(1 H, dd), 7.60,(1 H, d), 7.43,(2H, d), 7.27,(1 H, d), 6.98,(1H, m), 3.56,(4H, t), 3.30,(2H, m), 2.35-2.32,(6H, m), 2.19,(3H, s), 1.69,(2H, m). LCMS: retention time 2.42min, MH+448.
Example 14: N-r6-Methyl-4'-((f4-(4-methylpiperazin-1-yl)benzvnamino)carbonyl)- 1 , 1 '-biphenyl-3-vnthiophene-3-carboxamide
Example 15: N 6-Methyl-4'-r((3-r(4-methylpiperazin-1- yl)methvπphenyl>amino)carbonvn-1.1'-biphenyl-3-yl)thiophene-3-carboxamide
General Method A:
{3'-[(3-Thiophenylcarbonyl)amino]-6'-methyl-1 , 1 '-biphen-4-yl}carboxylic acid (Intermediate 1, 40mg, 0.12mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (27mg, 0.14mmol), HOBT (19mg, 0.14mmol) and the appropriate amine
(0.13mmol) were dissolved in DMF (5ml). DIPEA (25μl, 0.14mmol) was added to the solution which was then stirred for 16 hours at 20°C. The solvent was removed in vacuo and the residue was redissolved in ethyl acetate and washed with water. The ethyl acetate layer was separated, dried (magnesium), concentrated in vacuo and purified by mass-directed HPLC.
Figure imgf000032_0001
(a) {3'-[(3-Thiophenylcarbonyl)amino]-6'-methyl-1 , 1 '-biphen-4-yl}carboxylic acid (Intermediate 1)
A solution of lithium hydroxide monohydrate (541mg, 12.9 mmol) in water (8ml) was added to a solution of methyl {3'-[(3-thiophenylcarbonyl)amino]-6'-methyl-1,1'-biphen-4- yljcarboxylate (Intermediate 2, 1.37g, 4.3mmol) in THF (10ml). The reaction was refluxed for 4 hours. Solvent was evaporated in vacuo, hydrochloric acid (0.5M,50ml) was added and the product was extracted into ethyl acetate (2 x 50ml). The solvent was evaporated in vacuo to afford {3'-[(3-thiophenylcarbonyl)amino]-6'-methyl-1,1'- biphen-4-yl}carboxylic acid (1.68g, 98%).
NMR: δH [2H6] - DMSO 13.10,(1H, bs), 8.33,(1 H, dd), 8.03,(2H, d), 7.72,(1H, dd), 7.68- 7.60,(3H, m) 7.50,(2H, d), 7.30,(1 H, d), 2.20,(3H, s). LCMS: MH+ 338, retention time 3.47minutes.
(b) Methyl {3'-[(3-thiophenylcarbonyl)amino]-6'-methyl-1 ,1 '-biphen-4-yl}carboxylate (Intermediate 2)
Methyl (3'-amino-6'-methyl-1,1'-biphen-4-yl)carboxylate (1.45g, 6.0mmol), thiophene-3- carboxylic acid (0.846g, 6.6mmol), HOBT (0.973g, 7.2mmol) and 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.38g, 7.2mmol) were dissolved in DMF (10ml). DIPEA (1.26ml, 7.2mmol) was added to the stirred solution, which was then stirred for 16 hours at 20°C. The solvent was removed in vacuo and the residue dissolved in ethyl acetate. The ethyl acetate solution was washed sequentially with aqueous sodium hydrogen carbonate (80ml) and hydrochloric acid (0.5M, 80ml), then dried (magnesium sulphate). The solvent was removed in vacuo and the residue was purified by silica biotage chromatography eluting with 4:1 cyclohexane:ethyl acetate. To give methyl {3'-[(3-thiophenylcarbonyl)amino]-6'-methyl-1 ,1'-biphen-4- yl}carboxylate (1.78g, 84%). NMR: δH [2H6] - DMSO 10.1,(1H, s), 8.33,(1H, m), 8.05,(2H, d), 7.72,(1H, dd), 7.70- 7.60,(3H, m) 7.52,(2H, d), 7.30,(1 H, d), 3.89,(3H, s), 2.20,(3H, s). LCMS: MH+ 352, retention time 3.64minutes.
Example 16: N-f6-Methyl-4'-((r4-(4-methylpiperazin-1-yl)benzyllamino)carbonyl)-
1 , 1 '-biphenyl-3-vnisoxazole-3-carboxamide
Methyl {3'-[(3-isoxazolylcarbonyl)amino]-6'-methyl-1 , 1 '-biphen-4-yl}carboxylate (Intermediate 3, 640mg, 1.9mmol) was dissolved in THF (10ml) and a solution of lithium hydroxide monohydrate (252mg, 6.0mmol) in water (8ml) was added. The reaction was refluxed for 4 hours and then evaporated in vacuo. The residue was dissolved in DMF
(4ml), HOBT (54mg, 0.4mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (77mg, 0.4mmol) and DIPEA (70μl, 0.4mmol) were added. The mixture was stirred for 5 hours at 20°C. Water (40ml) and ethyl acetate (30ml) were added. After thorough mixing the ethyl acetate layer was separated. The water layer was extracted again with ethyl acetate (2 x 30ml). Ethyl acetate layers were combined, dried and evaporated in vacuo. The crude product was purified by mass-directed HPLC to yield N-[6-methyl-4'-({[4-(4-methylpiperazin-1 -yl)benzyl]amino}carbonyl)-1 , 1 '-biphenyl-3- yl]isoxazole-3-carboxamide (13mg, 1.5%) NMR: δH [2H6] - DMSO 10.7,(1 H, s), 9.16,(1 H, d), 9.00,(1 H, bt), 7.96,(2H,d), 7.72,(2H, dd+d), 7.45 ,(2H, d), 7.30,(1 H, d) 7.19,(2H, d), 6.90,(2H, d), 4.40,(2H, d), 3.10,(4H, m)
2.47,(4H, m), 2.22,(3H, s), 2.20,(3H, s). LCMS: MH+ 510, retention time 2.54minutes.
(a) Methyl {3'-[(3-isoxazolylcarbonyl)amino]-6'-methyl-1 , 1 '-biphen-4-yl}carboxylate (Intermediate 3)
Methyl (3'-amino-6'-methyl-1,1'-biphen-4-yl)carboxylate (0.483g, 2.0mmol), isoxazole-3- carboxylic acid (0.248g, 2.2mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.460g, 2.4mmol) and HOBT (0.324g, 2.4mmol) were dissolved in DMF (5ml). DIPEA (420μl, 2.4 mmol) was added to the solution, which was then stirred for 5 hours at 20°C. Ethyl acetate (50ml) and water (50ml) were added. The ethyl acetate layer was separated and washed sequentially with saturated sodium hydrogen carbonate (2 x 50ml) and hydrochloric acid (0.5M, 2 x 50ml), then dried (magnesium sulphate). The solvent was removed in vacuo to yield methyl {3'-[(3- isoxazolylcarbonyl)amino]-6'-methyl-1,1'-biphen-4-yl}carboxylate (650mg, 96%). LCMS: MH+ 337, retention time 3.42 minutes.
Example 17: N-r6-Methyl-4'-((f3-(morpholin-4-ylmethyl)benzvnamino)carbonyl)-1.1 '- biphenyl-3-vπ-3-furamide Example 18: tert-Butyl 4-f((f5'-(3-furoylamino)-2'-methyl-1.1 '-biphenyl-4- vπcarbonyl>amino)methvnpiperidine-1-carboxylate
Example 19: N-f6-Methyl-4'-((f2-(4-methylpiperazin-1-yl)phenvnamino)carbonyl)- 1.1 '-biphenyl-3-vπ-3-furamide
Example 20: N-(6-Methyl-4'-f((2-r(4-methylpiperazin-1- yl)methyπphenyl)amino)carbonvn-1 , 1 '-biphenyl-3-yl)-3-furamide
Example 21 : N-r6-Methyl-4'-({r3-(4-methylpiperazin-1-yl)phenyllamino)carbonyl)- 1 , 1 '-biphenyl-3-vn-3-furamide
Example 22: N-(6-Methyl-4'-(f(3-morpholin-4-ylpropyl)amino1carbonyl)-1,1'- biphenyl-3-yl)-3-furamide
Example 23: N-r4'-((f3-(1 H-lmidazol-1-yl)proρyllaminok.arbonyl)-6-methyl-1.1'- biphenyl-3-yll-3-furamide
General Method B:
[3'-(3-Furoylamino)-6'-methyl-1,1'-biphen-4-yl]carboxylic acid (50mg), amine (0.155mmol), HATU (59.2mg), HOBT (21 mg) and DIPEA (27μl) in DMF (2ml) were stirred for 18hours at room temperature. The reaction was diluted with ethyl acetate (75ml), washed with water (2x 30ml), dried (magnesium sulphate) and reduced to dryness under vacuum. The residue was purified on a silica flash column (40g) eluting with DCM / methanol / triethylamine (95.5:2.5:2).
Figure imgf000034_0001
Figure imgf000035_0001
Example 24: N-f4'-((f3-(1 H-lmidazol-1 -yl)propynamino)carbonyl)-6-methyl-1.1 '- biphenyl-3-vnthiophene-3-carboxamide
Example 25: tert-Butyl 4-f f((2'-methyl-5'-f(thien-3-ylcarbonyl)amino1-1.1 '-biphenyl-4- yl)carbonyl)aminolmethyl}piperidine-1-carboxylate
Example 26: N-(6-Methyl-4'-{f(3-morpholin-4-ylpropyl)amino1carbonyl>-1 , 1 '- biphenyl-3-yl)thiophene-3-carboxamide
Example 27: N-f6-Methyl-4'-((r3-(4-methylpiperazin-1-yl)propyl1amino)carbonyl)- 1.1 '-biphenyl-3-vnthiophene-3-carboxamide
Example 28: N-r6-Methyl-4'-((f2-(4-methylpiperazin-1 -yl)ethvnamino>carbonyl)-1 , 1 '- biphenyl-3-vnthiophene-3-carboxamide
General Method C:
{3'-[(3-Thiophenylcarbonyl)amino]-6'-methyl-1 , 1 '-biphen-4-yl}carboxylic acid (Intermediate 1, 19mg, 0.06mmol), triethylamine (13ul) and 1-(methylsulphonyl)-1H- benzotriazole (12mg, 0.06mmol) were mixed in THF (0.5ml) and heated at reflux for 4 hours. The reaction was concentrated under vacuum and partitioned between chloroform (3ml) and water (2ml) and the organics reduced to dryness under vacuum. The residue was redissolved in THF (0.5ml) and was mixed with the amine (0.06mmol). After 20 hours the reaction was loaded onto an SPE (aminopropyl, 0.5g) and eluted with chloroform to give the desired product.
Figure imgf000035_0002
Example 29: N-f6-Methyl-4'-((f3-(4^methylpiperazin-1-yl)phenvπamino|carbonyl)- 1 , 1 '-biphenyl-3-vπisoxazole-5-carboxamide
{3'-[(5-lsoxazolylcarbonyl)amino]-6'-methyl-1 , 1 '-biphen-4-yl}carboxylic acid (Intermediate 4, 30mg), 3-(4-methyl-1-piperazinyl)aniline (17.8mg), HATU (35mg), HOBT (13mg) and DIPEA (48μl) in DMF (1ml) were stirred for 18hours at room temperature. The reaction was purified by mass-directed autoprep to give N-[6-methyl- 4'-({[3-(4-methylpiperazin-1 -yl)phenyl]amino}carbonyl)-1 , 1 '-biphenyl-3-yl]isoxazole-5- carboxamide. LCMS: MH+ 496, retention time 2.63minutes.
(a) {3'-[(5-lsoxazolylcarbonyl)amino]-6'-methyl-1 ,1 '-biphen-4-yl}carboxylic acid (Intermediate 4)
Methyl {3'-[(5-isoxazolylcarbonyl)amino]-6'-methyl-1 , 1 '-biphen-4-yl}carboxylate (Intermediate 5, 2.84g), sulphuric acid (1M, 50ml) and ethanol (100ml) were heated at
75°C for 2hours. The reaction was concentrated under vacuum and the resulting precipitate filtered off and washed with water. The resulting solid was purified on a flash silica column eluting with an ethyl acetate / cyclohexane gradient (33-66% ethyl acetate). Evaporation of the solvent under vacuum gave{3'-[(5- isoxazolylcarbonyl)amino]-6'-methyl-1 ,1'-biphen-4-yl}carboxylic acid.
LCMS: MNH4 + 340, retention time 3.11 minutes.
(b) Methyl {3'-[(5-isoxazolylcarbonyl)amino]-6'-methyl-1 , 1 '-biphen-4-yl}carboxylate (Intermediate 5)
Methyl (3'-amino-6'-methyl-1 ,1'-biphen-4-yl)carboxylate (2g), HATU (3.16g), DIPEA (4.32ml), 5-isoxazolecarboxylic acid (0.95g) in DMF (30ml) and ethyl acetate (50ml) were stirred at room temperature for 2hours. The reaction was diluted with ethyl acetate (500ml), washed with hydrochloric acid (0.5M, 2x 200ml), aqueous sodium hydrogen carbonate (2x 200ml) and dried (magnesium sulphate). The solvent was evaporated in vacuo to give methyl {3'-[(5-isoxazolylcarbonyl)amino]-6'-methyl-1,1'- biphen-4-yl}carboxylate. LCMS: [M-H]' 335, retention time 3.17minutes.
Abbreviations
DCM Dichloromethane
DIPEA N,N-Diisopropylethylamine
DME Dimethoxyethane
DMF Dimethylformamide
DMSO Dimethylsulphoxide HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HBTU O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate HOBT 1-Hydroxybenzotriazole hydrate
PyBOP Benzotriazol-1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate
SPE Solid phase extraction
THF Tetrahydrofuran
The activity of the compounds of the invention as p38 inhibitors may be demonstrated in the following assays:
p38 Kinase Assay
The peptide substrate used in the p38 assay was biotin-IPTSP.TTTYFFFRRR- amide. The p38 and MEK6 proteins were purified to homogeneity from E.coli expression systems. The fusion proteins were tagged at the N-terminus with Glutathione-S-Transferase (GST). The maximum activation was achieved by incubating 20uL of a reaction mixture of 30nM MEK6 protein and 120nM p38 protein in the presence of 1.5uM peptide and 10mM Mg(CH3CO2)2 in 100mM HEPES, pH 7.5, added to 15uL of a mixture of 1.5uM ATP with O.OδuCi [g-33P]ATP, with or without 15uL of inhibitor in 6%DMSO. The controls were reactions in the presence (negative controls) or absence (positive controls) of 50 mM EDTA. Reactions were allowed to proceed for 60 min at room temperature and quenched with addition of 50uL of 250mM EDTA and mixed with 150uL of Streptavidin SPA beads (Amersham) to 0.5mg/reaction. The Dynatech Microfluor white U-bottom plates were sealed and the beads were allowed to settle overnight. The plates were counted in a Packard TopCount for 60 seconds. IC50 values were obtained by fitting raw data to %l = 100*(1-(I-C2)/(C1-C2)), where I was CPM of background, C1 was positive control, and C2 was negative control.
α P38 Fluorescence Polarisation Method α P38 was prepared in house. SB4777790-R Ligand was diluted in HEPES containing MgCI2, CHAPS, DTT and DMSO. This was added to blank wells of a Black NUNC 384 well plate, α P38 was added to this ligand mixture then added to the remainder of the 384 well plate containing controls and compounds. The plates were read on an LJL Analyst and Fluorescence Anisotropy used to calculate the compound inhibition.
The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process or use claims and may include, by way of example and without limitation, one or more of the following claims:

Claims

Claims:
1. A compound of formula (I):
1
Figure imgf000039_0001
wherein
X is a bond or a phenyl group which may be optionally substituted;
R1 is selected from an optionally substituted five- to seven-membered heterocyclic ring, an optionally substituted five- to seven-membered heteroaryl ring and an optionally substituted fused bicyclic ring;
R2 is selected from hydrogen, d.6alkyl and -(CH2)p-C3-7cycloalkyl; or when X is a bond and m and n are both zero, R1 and R2, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing up to one additional heteroatom selected from oxygen and nitrogen, which can be optionally substituted by d^alkyl
R3 is the group -NH-CO-R4;
R4 is selected from hydrogen, d-6alkyl, C^alkoxy, -(CH2)q-C3. cycloalkyl, trifluoromethyl, -(CH2)rphenyl optionally substituted by R5 and/or R6, -(CH2)rheteroaryl optionally substituted by R5 and/or R6, -(CH2)rheterocyclyl optionally substituted by R5 and/or R6 and -(CH2)rfused bicyclyl optionally substituted by R5 and/or R6;
R5 is selected from C^alkyl, d-6alkoxy, -(CH2)q-C3.7cycloalkyl, -CONR7R8, - NHCOR8, -SO2NHR7, -NHSO2R8, halogen, -(CH2)SNR9R10, oxy, trifluoromethyl, phenyl optionally substituted by one or more R6 groups and heteroaryl wherein the heteroaryl may be optionally substituted by one or more R6 groups;
R6 is selected from d^alkyl, d^alkoxy, halogen, trifluoromethyl and -NR9R10; or R5 and R6, together with the carbon atoms to which they are bound, form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R5 and R6 may optionally contain one or two heteroatoms selected from oxygen, nitrogen and sulfur; R7 is selected from hydrogen, d.6alkyl and phenyl wherein the phenyl group may be optionally substituted by one or more R6 groups;
R8 is selected from hydrogen and d-6alkyl; or R7 and R8, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-Rx, wherein the ring may be substituted by up to two d.6alkyl groups;
Rx is selected from hydrogen and methyl;
R9 is selected from hydrogen, C^alkyl and -(CH2)q-C3.7cycloalkyl optionally substituted by d-6alkyl;
R10 is selected from hydrogen and d-6alkyl; or R9 and R10, together with the nitrogen atom to which they are bound, form a three- to seven-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and nitrogen, wherein the ring may contain up to one double bond and the ring may be substituted by one or more R11 groups;
R11 is selected from d-βalkyl, oxy, -CH2Od^alkyl, trichloromethyl and -N(d. 6alkyl)2;
U is selected from methyl and halogen;
W is selected from methyl and chlorine; V and Y are each selected independently from hydrogen, methyl and halogen; m and n are independently selected from 0, 1 and 2, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups selected independently from d.6alkyl and the sum of m+ n is from 0 to 4; p, q and r are independently 0 or 1 ; s is 0, 1, 2 or 3; t is selected from 0, 1 and 2; or a pharmaceutically acceptable salt or solvate thereof.
2. A compound according to claim 1 wherein R1 is optionally substituted by up to three substituents selected from d-6alkyl, d-ealkoxy, oxy, halogen, hydroxyC^alkyl, -
N(C1^alkyl)2, -CH2-N(Cι^alkyl)2, -CO2C1.6alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano.
3. A compound according to claim 1 or 2 wherein X is optionally substituted phenyl, and R1 is selected from optionally substituted pyrrolidinyl, furyl, pyrrolyl, imidazolyl, imidazolidinyl, pyrazolyl, tetrazolyl, oxazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholino, pyridyl, pyrimidinyl, thienyl, benzimidazolyl and quinolyl; wherein the optional substituents for R1 are selected independently from d-ealkyl, d.6alkoxy, oxy, halogen, hydroxyd.6alkyl, -N(C1^alkyl)2 and -CH2-N(C1-6alkyl)2.
4. A compound according to claim 1 or 2 wherein X is a bond, and R1 is selected from an optionally substituted pyrrolidinyl, isoxazolyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholino, pyridyl, tetrahydrofuranyl, tetrahydrothiophenyl and quinolyl; wherein the optional substituents for R are selected independently from d-βalkyl, d-ealkoxy, oxy, halogen, hydroxyd.6alkyl, ■N(C1-6alkyl)2, -CH2-N(d^alkyl)2, -CO2C1^alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano.
5. A compound according to any one of the preceding claims wherein R2 is selected from hydrogen, d^alkyl and -CH2-cyclopropyl.
6. A compound according to any one of the preceding claims wherein R4 is selected from -(CH2)rphenyl optionally substituted by R5 and/or R6 and -(CH2)rheteroaryl optionally substituted by R5 and/or R6.
7. A compound according to claim 6 wherein R4 is -(CH2)rheteroaryl optionally substituted by R5 and/or R6.
8. A compound according to any one of the preceding claims wherein m and n are independently selected from 0, 1 and 2, and the sum of m+n is from 0-3.
9. A compound according to claim 1 as defined in any one of Examples 1 to 29, or a pharmaceutically acceptable salt or solvate thereof.
10. A process for preparing a compound according to any one of claims 1 to 9 which comprises:
(a) reacting a compound of formula (XII)
Figure imgf000042_0001
(XII)
wherein R1, R2, U, V, W, X, Y, m, n and t are as defined in claim 1, with a compound of formula (XIII)
R4CO,H
(XIII) wherein R4 is as defined in claim 1 , under amide forming conditions, optionally converting the acid compound (XIII) to an activated form of the acid before reaction with the amine compound (XII), or
(b) reacting a compound of formula (XIV)
Figure imgf000042_0002
(XIV) wherein R3, U, V, W, Y and t are as defined in claim 1 , with a compound of formula (XV)
Ri(CH2)mX(CH2)nNR2H (XV)
wherein R^ , R2, X, m and n are as defined in claim 1, under amide forming conditions.
11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt or solvate thereof, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
12. A method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase comprising administering to a patient in need thereof a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt or solvate thereof.
13. A compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt or solvate thereof for use in therapy.
14. Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for use in the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.
PCT/EP2002/011572 2001-10-17 2002-10-16 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors WO2003033483A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02782928A EP1436272B1 (en) 2001-10-17 2002-10-16 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
US10/492,697 US7151118B2 (en) 2001-10-17 2002-10-16 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors
JP2003536223A JP2005508967A (en) 2001-10-17 2002-10-16 Biphenylcarboxylic acid amide derivatives as p38 kinase inhibitors
DE60226469T DE60226469D1 (en) 2001-10-17 2002-10-16 BIPHENYL CARBOXYL ACID AMID DERIVATIVES AS P38 KINASE INHIBITORS
US11/556,285 US7309800B2 (en) 2001-10-17 2006-11-03 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0124933.3 2001-10-17
GBGB0124933.3A GB0124933D0 (en) 2001-10-17 2001-10-17 Chemical compounds

Publications (1)

Publication Number Publication Date
WO2003033483A1 true WO2003033483A1 (en) 2003-04-24

Family

ID=9924029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011572 WO2003033483A1 (en) 2001-10-17 2002-10-16 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors

Country Status (8)

Country Link
US (2) US7151118B2 (en)
EP (1) EP1436272B1 (en)
JP (1) JP2005508967A (en)
AT (1) ATE394383T1 (en)
DE (1) DE60226469D1 (en)
ES (1) ES2305317T3 (en)
GB (1) GB0124933D0 (en)
WO (1) WO2003033483A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089876A1 (en) * 2003-04-09 2004-10-21 Smithkline Beecham Corporation Biphenylcarboxylic amide derivatives as p38 kinease inhibitors
WO2004092136A1 (en) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and use thereof
WO2005012241A2 (en) * 2003-07-25 2005-02-10 Novartis Ag p-38 KINASE INHIBITORS
WO2005014550A1 (en) * 2003-08-11 2005-02-17 Smithkline Beecham Corporation 3- aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
US7425555B2 (en) 2002-04-30 2008-09-16 Smithkline Beecham Corporation Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
US7652044B2 (en) 2003-06-03 2010-01-26 Novartis A.G. P-38 inhibitors
US7863314B2 (en) 2003-06-26 2011-01-04 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
US7932247B2 (en) * 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11452713B2 (en) 2016-02-29 2022-09-27 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods for treating low-proliferative disseminated tumor cells

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (en) * 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
MXPA04007838A (en) * 2002-02-12 2004-10-15 Smithkline Beecham Corp Nicotinamide derivates useful as p38 inhibitors.
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20040242572A1 (en) * 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US8008303B2 (en) * 2005-09-16 2011-08-30 Astrazeneca Ab Biphenyl derivatives and their use in treating hepatitis C
GB0612026D0 (en) 2006-06-16 2006-07-26 Smithkline Beecham Corp New use
AU2010258853B2 (en) 2009-06-09 2014-07-31 Nantbio, Inc. Triazine derivatives and their therapeutical applications
AU2010258964B2 (en) 2009-06-09 2014-09-11 Nantbio, Inc. Benzyl substituted triazine derivatives and their therapeutical applications
WO2010144586A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015954A1 (en) * 1993-12-07 1995-06-15 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
WO1999032463A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
WO2000071535A1 (en) * 1999-05-21 2000-11-30 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
EP0346841A3 (en) 1988-06-16 1991-01-09 Ciba-Geigy Ag 1-aryl-naphthoic acid amide and microbicides containing these
MX16687A (en) 1988-07-07 1994-01-31 Ciba Geigy Ag BIARILE COMPOUNDS AND PROCEDURE FOR THE PREPARATION.
EP0430033A3 (en) 1989-11-24 1991-09-11 Ciba-Geigy Ag Microbicidal agents
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ATE204262T1 (en) 1991-09-18 2001-09-15 Glaxo Group Ltd BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
TW240217B (en) 1992-12-30 1995-02-11 Glaxo Group Ltd
IL108630A0 (en) 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
GB2276161A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
DK0716649T3 (en) 1993-08-31 1999-02-08 Pfizer 5-Arylindole derivatives
EP0716656A1 (en) 1993-09-03 1996-06-19 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
EP0724580A1 (en) 1993-10-19 1996-08-07 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
GB9326008D0 (en) 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
JPH09512804A (en) 1994-05-06 1997-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Biphenylcarboxamides useful as 5-HT1D antagonists
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
JPH11501049A (en) 1995-04-04 1999-01-26 グラクソ、グループ、リミテッド Imidazo [1,2-a] pyridine derivative
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AU709961B2 (en) 1995-07-10 1999-09-09 Dow Chemical Company, The Polynitrile oxides
USRE39088E1 (en) 1995-08-22 2006-05-02 Japan Tobacco, Inc. Amide compounds and use of the same
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
NZ327044A (en) 1996-01-11 2000-01-28 Smithkline Beecham Corp Substituted imidazole compounds
FR2754260B1 (en) 1996-10-04 1998-10-30 Adir NOVEL SUBSTITUTED DERIVATIVES OF BIPHENYL OR PHENYLPYRIDINE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
WO1998052937A2 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase
JP2002504909A (en) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション New substituted pyrazole and pyrazoline compounds
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
AU7976998A (en) 1997-06-19 1999-01-04 Du Pont Merck Pharmaceutical Company, The (amidino)6-membered aromatics as factor xa inhibitors
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
KR100382619B1 (en) 1997-09-05 2003-05-09 글락소 그룹 리미티드 2,3-Diaryl-Pyrazolo[1,5-B]Pyridazines Derivatives, Their Preparation and Their Use As Cyclooxygenase 2(COX-2) Inhibitors
CA2304713C (en) 1997-10-14 2003-06-10 Asahi Kasei Kogyo Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
JPH11218884A (en) 1998-02-03 1999-08-10 Konica Corp Silver halide photographic sensitive material
DE19817461A1 (en) 1998-04-20 1999-10-21 Basf Ag New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
AU749293B2 (en) 1998-05-15 2002-06-20 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US6130235A (en) 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
AU772477B2 (en) 1998-08-28 2004-04-29 Scios Inc. Inhibitors of p38-alpha kinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002526482A (en) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド inhibitors of p38
ES2228127T3 (en) 1998-11-03 2005-04-01 Glaxo Group Limited DERIVATIVES OF PIRAZOLOPIRIDINE AS SELECTIVE COH-2 INHIBITORS.
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1150948A1 (en) 1999-02-11 2001-11-07 Cor Therapeutics, Inc. ALKENYL AND ALKYNYL COMPOUNDS AS INHIBITORS OF FACTOR Xa
ES2216631T3 (en) 1999-02-27 2004-10-16 Glaxo Group Limited PIRAZOLPIRIDINAS.
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6509361B1 (en) 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
US6638980B1 (en) 1999-05-24 2003-10-28 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6545055B1 (en) 1999-05-24 2003-04-08 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CA2382751A1 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibitors of factor xa
DE19932571A1 (en) 1999-07-13 2001-01-18 Clariant Gmbh Process for the preparation of biarylene using palladophosphacyclobutane catalysis
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6576632B1 (en) 1999-08-27 2003-06-10 Pfizer Inc Biaryl compounds useful as anticancer agents
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
NZ512957A (en) 1999-11-10 2005-01-28 Ortho Mcneil Pharm Inc Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a] pyrimidines and their use in inhibiting in vitro secretion of TNF-alpha and IL-1beta to treat neurodegenerative diseases
MXPA02009319A (en) 2000-03-22 2003-03-12 Vertex Pharma Pyridine derivatives as inhibitors of p38.
AU5878101A (en) 2000-05-18 2001-11-26 Daiichi Pharmaceutical Co., Ltd. Novel benzofuran derivatives
PE20020506A1 (en) 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
CA2429628A1 (en) 2000-11-17 2002-05-23 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
DE10059418A1 (en) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
DE10060807A1 (en) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
DE10063008A1 (en) 2000-12-16 2002-06-20 Merck Patent Gmbh carboxamide
DE10110749A1 (en) 2001-03-07 2002-09-12 Bayer Ag Substituted aminodicarboxylic acid derivatives
ATE323701T1 (en) 2001-03-09 2006-05-15 Pfizer Prod Inc TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS
EP1383731B1 (en) 2001-04-06 2009-08-05 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
FR2824827B1 (en) 2001-05-17 2004-02-13 Fournier Lab Sa NOVEL 5-PHENYL-1H-INDOLE ANTAGONIST DERIVATIVES OF INTERLEUKIN-8 RECEPTORS
AR037233A1 (en) 2001-09-07 2004-11-03 Euro Celtique Sa PIRIDINAS ARIL REPLACED, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
MXPA04007838A (en) 2002-02-12 2004-10-15 Smithkline Beecham Corp Nicotinamide derivates useful as p38 inhibitors.
US20030225089A1 (en) 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
US20040116479A1 (en) 2002-10-04 2004-06-17 Fortuna Haviv Method of inhibiting angiogenesis
US7136850B2 (en) 2002-12-20 2006-11-14 International Business Machines Corporation Self tuning database retrieval optimization using regression functions
CA2415049A1 (en) * 2002-12-23 2004-06-23 William J. Wagner Windshield wiper blade slapper apparatus
CA2534990A1 (en) 2003-07-25 2005-02-10 Novartis Ag P-38 kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015954A1 (en) * 1993-12-07 1995-06-15 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
WO1999032463A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
WO2000071535A1 (en) * 1999-05-21 2000-11-30 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425555B2 (en) 2002-04-30 2008-09-16 Smithkline Beecham Corporation Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
WO2004089876A1 (en) * 2003-04-09 2004-10-21 Smithkline Beecham Corporation Biphenylcarboxylic amide derivatives as p38 kinease inhibitors
WO2004092136A1 (en) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and use thereof
US7652044B2 (en) 2003-06-03 2010-01-26 Novartis A.G. P-38 inhibitors
US8580838B2 (en) 2003-06-26 2013-11-12 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
US8410160B2 (en) 2003-06-26 2013-04-02 Novartis Ag 5-membered heterocycle-based P38 kinase inhibitors
US8242117B2 (en) 2003-06-26 2012-08-14 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
EP2298743A1 (en) 2003-06-26 2011-03-23 Novartis AG 5-membered heterocycle-based P38 kinase inhibitors
US7863314B2 (en) 2003-06-26 2011-01-04 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
US7754726B2 (en) 2003-07-25 2010-07-13 Novartis Ag Benzamide derivatives as p-38 kinase inhibitors
WO2005012241A3 (en) * 2003-07-25 2005-04-14 Triad Therapeutics Inc p-38 KINASE INHIBITORS
US7700622B2 (en) 2003-07-25 2010-04-20 Novartis Ag p-38 kinase inhibitors
EP1990338A2 (en) 2003-07-25 2008-11-12 Novartis AG Biphenylcyclopropylamides as p-38 Kinase inhibitors
CN100447137C (en) * 2003-07-25 2008-12-31 诺瓦提斯公司 P-38 kinase inhibitors
WO2005012241A2 (en) * 2003-07-25 2005-02-10 Novartis Ag p-38 KINASE INHIBITORS
JP2007501831A (en) * 2003-08-11 2007-02-01 スミスクライン ビーチャム コーポレーション 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxide as P38 kinase inhibitor
JP4845733B2 (en) * 2003-08-11 2011-12-28 スミスクライン ビーチャム コーポレーション 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxide as P38 kinase inhibitor
WO2005014550A1 (en) * 2003-08-11 2005-02-17 Smithkline Beecham Corporation 3- aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
US7932247B2 (en) * 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US11452713B2 (en) 2016-02-29 2022-09-27 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods for treating low-proliferative disseminated tumor cells
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4

Also Published As

Publication number Publication date
EP1436272A1 (en) 2004-07-14
ATE394383T1 (en) 2008-05-15
ES2305317T3 (en) 2008-11-01
US7151118B2 (en) 2006-12-19
DE60226469D1 (en) 2008-06-19
US20070105860A1 (en) 2007-05-10
EP1436272B1 (en) 2008-05-07
GB0124933D0 (en) 2001-12-05
US7309800B2 (en) 2007-12-18
US20050020540A1 (en) 2005-01-27
JP2005508967A (en) 2005-04-07

Similar Documents

Publication Publication Date Title
EP1436272B1 (en) Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
US7396843B2 (en) 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7208629B2 (en) 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
EP1864975B1 (en) Nicotinamide derivates useful as P38 inhibitors
WO2003033457A1 (en) Biphenyl-derivatives as p38-kinase inhibitors
US7642276B2 (en) Fused heteroaryl derivatives for use as P38 kinase inhibitors
US7166623B2 (en) 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
EP1436269A1 (en) Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
WO2003032970A1 (en) 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
EP1435934A1 (en) 5'-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
EP1435949A1 (en) 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003536223

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10492697

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002782928

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002782928

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002782928

Country of ref document: EP